theMednetRegister

NCI-CCC Tumor Board Question   

These are questions being discussed by academics at NCI-Cancer Centers

Questions discussed in this category

Do you have a certain tumor size threshold in which you change chemotherapy recommendations for a small, triple negative breast cancer?
(For instance, TCx4 instead of ddAC->T for smaller tumors?)Does this affect your decision about treating with neoadjuvant versus adjuvant chemother...
5 Answers available
How would you manage a patient with marginal zone lymphoma who progress after treatment on a BKTI?
1 Answer available
What do you recommend for patients with stage 3 MSI-H colorectal cancer who are ineligible for oxaliplatin-based adjuvant therapy?
4 Answers available
Would you consider daratumumab monotherapy as standard of care for smoldering multiple myeloma based on the AQUILA trial?
AQUILA trial - NEJM
3 Answers available
How do you approach patients with AL amyloidosis with t(11;14) who have not achieved a hematologic complete response to induction therapy with 6 cycles of Dara-CyBorD?
Specifically, in the setting of patients that have had a PR or VGPR and are not actively progressing. 
2 Answers available
What is your current practice for de-escalation of frequency of administration of bispecific antibodies among responders in patients with relapsed/refractory multiple myeloma?
1 Answer available
In which clinical settings do you use the Cerianna (fluoroestradiol F18) PET scan for breast cancer?
2 Answers available
In patients with cholangiocarcinoma who qualify for HAIP therapy, would you recommend treating with chemotherapy and immunotherapy?
PUMP-2 trial combined FUDR via HAIP with gemcitabine and cisplatin, no immunotherapy was on the protocol. 
3 Answers available
How do you approach pelvic radiation therapy for a patient with multiple myeloma who needs more intensive therapy (e.g., Dara-KRd or impending CAR-T) with a risk of cytopenias?
For example, a large iliac or sacral plasmacytoma causing symptoms. Both medical oncologists and radiation oncologists get nervous about RT-related cy...
1 Answer available
How often do you assess for frailty in your clinical practice for patients with Multiple Myeloma and what tool do you use?
For example: eyeball test, simplified frailty assessment (Facon et al.), IMWG frailty score, ECOG only?
1 Answer available
For a patient with ENKTL nasal type (nose/sinus involvement) who has hepatic toxicity with pegasparaginase but a CR after 2 cycles of chemotherapy with a plan for "sandwich" radiotherapy - what, if any, chemotherapy would you resume after completion of radiation?
I am not sure there is much efficacy for a regimen that does not include asparaginase. The patient received 2 cycles of P-GemOx, then was admitted for...
2 Answers available
What is the role for adjuvant chemotherapy and/or radiation in ampullary carcinoma?
Ampullary carcinoma is not in the NCCN guidelines. Please address not only the role for therapy but the optimal regimen (i.e. Gem based, vs mFOLFIRINO...
1 Answer available
How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?
Most patients with PGNMID have no detectable disease in their marrow or blood and urine protein cannot adequately be monitored.
1 Answer available
How would you consolidate a patient with primary refractory double hit lymphoma with secondary CNS involvement?
At the time of initial diagnosis, there was no clear CNS involvement. When it became clinically apparent disease was refractory to EPOCH, there was CS...
2 Answers available
What is your preferred approach to a patient with myeloma who has refractory disease to Dara-VRd in the frontline setting?
2 Answers available
How are you dosing IVIG following BCMA CAR-T or bispecific antibodies in multiple myeloma?
Do you only offer it for patients with a documented IgG < 400? Do you check the IgG at all, or are you doing primary prophylaxis?
1 Answer available
How do you approach initial treatment for AL amyloidosis with excess plasmacytosis in the bone marrow, that has cardiac involvement and is not a transplant candidate?
Let's assume they have cardiac involvement and transplant may not be feasible. 
1 Answer available
How would you approach dose modifications and/or frequency of lenalidomide in patients with advanced renal impairment (eGFR <30)?
The FDA package insert suggests 2.5 mg daily in these settings, while the PrE1003 study demonstrated that a higher dose is feasible. Many oncologists ...
2 Answers available
What is your approach to determining fitness for patients to undergo CAR-T therapy for relapsed/refractory multiple myeloma, and any absolute perceived contraindications for CAR-T?
1 Answer available
In what scenarios (if ever) would you check peripheral blood flow cytometry in a patient with known multiple myeloma to evaluate for circulating plasma cells (CPCs) in the absence of an abnormal smear?
There are some retrospective data that CPCs are associated with worsened outcomes after transplantation. Anecdotally, CPCs could be collected as part ...
1 Answer available
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?
3 Answers available
Would ITCs in a single axillary node push you towards recommending adjuvant chemotherapy for a young woman with a T1a (<2mm) triple negative breast cancer?
Patient underwent an axillary dissection with ITCs in 1/23 nodes.
1 Answer available
For patients with well differentiated NET whose carcinoid symptoms are controlled on SSAs but have persistently elevated 5HIAA, would you consider adding telotristat for prevention of carcinoid heart disease?
How aggressive should we be in bringing elevated plasma/urine 5HIAA to normal levels in patients whose symptoms are controlled? Before we have the res...
1 Answer available
How would you treat an elderly patient with Stage IIA cHL with 3 nodal sites of involvement who has a contraindication to bleomycin?
DLCO 65% that is of unclear etiology but not due to disease and no cardiac or pulmonary functional limitations.
1 Answer available
How would you treat an elderly newly diagnosed tDLBCL that has previously seen R-CHOP and Bendamustine-Obinutuzumab prior to the transformative event?
7 Answers available
Do you consider post-NAC isolated tumor cells in LNs to be residual disease in TNBC to justify capecitabine?
Would clinical stage or nodal status affect your decision?
3 Answers available
Is there evidence for development of more severe autoimmune toxicities for young patients vs older patients on immune checkpoint inhibitors?
As immune checkpoint inhibitors have expanded into the neoadjuvant breast cancer setting, severe and unexpected autoimmune toxicities may cause delays...
1 Answer available
What chemotherapy regimen would you offer to a patient with DLBCL who was originally diagnosed and treated (R-CHOP) 15 years ago, now with a 2nd primary/late recurrence of DLBCL?
1 Answer available
Based on the DREAMM-7 and DREAMM-8 data, if approved again in the US, how would you incorporate belantamab mafadotin in your practice?
2 Answers available
Based on the IMROZ and BENEFIT data, would you recommend quadruplet therapy for non transplant eligible newly diagnosed multiple myeloma?
1 Answer available
Do you offer local consolidative therapy for patients with polymetastatic driver mutation-positive NSCLC who respond well to targeted therapy?
If so, when and to what extent? 
2 Answers available
How would you treat an elderly male with history of mantle cell lymphoma who relapsed after chemoimmunotherapy and cBTKi w/ multiple co-morbidities including CKD and CHF w/ low EF?
1 Answer available
How would you approach adjuvant systemic therapy for a pT3N0(i+) HR+/HER2 negative breast cancer with an intermediate oncotype in a post-menopausal woman?
3 Answers available
In 2024, do you consider isolated gain(1q) [not amp(1q)] to be a high-risk cytogenetic abnormality in multiple myeloma?
Most would argue that gain(1q) in combination with another high-risk feature constitutes ultra-high-risk multiple myeloma, and most would argue (with ...
1 Answer available
How long should we treat patients with newly diagnosed myeloma with bisphosphonates or RANKL inhibitors for their myeloma bone disease given recent data?
The OS benefit with Zometa was seen only in patients with myeloma bone disease achieving less than or equal to a partial response. SRE risk reduction ...
1 Answer available
How would you manage a patient with p53 mutated MCL who has progressed after a BTKi and CAR-T with a CD20 negative clone?
1 Answer available
Do you routinely offer ovarian suppression in addition to aromatase-inhibitor in premenopausal patients under 50 with an intermediate oncotype score (11-25)?
In the setting of the recent TailorRx data, would these patients be considered more high risk?
1 Answer available
Is there any value to getting a bone marrow biopsy at the time of biochemical relapse in multiple myeloma before switching to a new line of therapy?
For many clinical trials, a screening bone marrow biopsy is necessary to get a new baseline. Do you do the same in real-world practice?
3 Answers available
Do you resume zoledronic acid or denosumab at relapse in multiple myeloma?
Previous questions have focused on the newly diagnosed setting and choice of bisphosphonate versus denosumab. IMWG guidelines do recommend resuming zo...
2 Answers available
How might you alter treatment for a breast cancer patient receiving standard taxane-based adjuvant therapy who develops an adverse reaction to the taxane (e.g. severe pneumonitis) after completion of ddAC?
For a patient with high risk disease and a severe enough reaction that additional taxane-based therapy is contraindicated, do you consider alternate c...
2 Answers available
In which situations are you comfortable with alternative dosing of ovarian suppression (e.g Lupron q3m) for premenopausal patients during adjuvant breast cancer treatment?
2 Answers available
In the current myeloma landscape, do you make treatment decisions based on MRD results, either for MRD negativity or MRD resurgence?
2 Answers available
With the recent ODAC review of the commerically available CAR-T therapies in relapsed/refractory myeloma post 1-3 lines of therapy, what is your preferred regimen/therapy for first relapse, and which are the situations where you would absolutely consider CAR-T therapy at first relpase?
1 Answer available
For patients on commercial teclistamab who achieve a response, are there patient-specific or response-specific parameters that would prompt you to de-escalate therapy from once per week?
For example - minimum number of months of therapy, driving distance to clinic, at least a CR with or without MRD negativity?
3 Answers available
Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?
2 Answers available
For patients with triple negative breast cancer who have a minimal response to neoadjuvant chemotherapy, do you do additional testing to sub-categorize the cancer and find a potential target (e.g. androgen receptor, etc)?
7 Answers available
In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?
If CCRT is pursued, would you move forward with durvalumab consolidation? Assume the patient with ECOG PS 0 and no co-morbidities. How might this chan...
4 Answers available
Is post-mastectomy chest wall radiotherapy indicated for DCIS with very close (<1 mm) or positive margins?
4 Answers available
Would you extrapolate from EMBARK to use an ARPI other than enzalutamide in high risk biochemically recurrent prostate cancer for a patient with contraindications to enzalutamide?
1 Answer available
How would you treat a patient who received 2 cycles of R-CHOP for DLBCL who was subsequently diagnosed with follicular lymphoma?
Would you continue R-CHOP or would you switch therapy? 
1 Answer available
For a Jehovah's Witness patient with multiple myeloma, could you safely offer a BCMA-directed bispecific antibody or CAR-T therapy?
Please assume that IVIG is fine (as it is for many Jehovah's Witness patients, since IgG is often not considered a blood product per se).
2 Answers available
How would you treat an older patient with B symptoms and biopsy consistent with grade 3 follicular lymphoma but noted to have a PET scan with SUV readings of > 20?
1 Answer available
How would you manage a case of subcutaneous panniculitis-like T cell lymphoma (A/B) who is already on steroids and methotrexate for autoimmune disease?
1 Answer available
For muscle-invasive bladder cancer with predominant (>90%) squamous differentiation, would you consider cisplatin-based neoadjuvant chemotherapy prior to radical cystectomy or upfront surgery?
Would a PET avid pelvic lymph node without distant metastatic disease change your management?
1 Answer available
In which scenarios do you use vaginal estrogen in patients with history of HR positive breast cancer?
Do you feel differently about using these in patients with a history of HR-negative breast cancer?
1 Answer available
When would you feel comfortable with patients who have a history of hormone-receptor positive breast cancer using hormonal IUDs (e.g. Mirena)?
2 Answers available
Are there any circumstances where you recommend early institution of systemic therapy for patients with solitary plasmacytoma?
Specifically, do you offer closer follow-up for certain patients after local radiation?
3 Answers available
How would you manage biopsy-proven DLBCL in a patient who was treated with 6 cycles of R-CHOP 15 years ago for DLBCL?
Would you consider this de novo DLBCL (unable to assess for clonality)? How would you handle prior anthracycline exposure? 
1 Answer available
In light of RIGHT Choice trial data, when will you opt for a CDK 4/6 inhibitor plus AI instead of chemotherapy in patients with metastatic HR-positive HER2-negative breast cancer with visceral crisis?
RIGHT Choice trial presented at SABCS 2022
3 Answers available
Would you offer definitive local therapy to a patient with ER/PR+, Her2 neg breast cancer with oligometastatic disease that responded well to CDK 4/6 inhibitor +AI, despite NRG-BR002 results?
Young healthy patient, ER/PR positive HER2 negative right breast cancer with a synchronous single site of oligometastatic disease in the right 4th rib...
2 Answers available
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
2 Answers available
Are there any scenarios you would use CDK 4/6i to treat HR-positive HER2-positive breast cancer in combination with anti-HER2 agents?
1 Answer available
How do you manage adjuvant endocrine therapy for microinvasive HR-positive disease measuring >=1mm in extension?
1 Answer available
How would you treat a patient with Hodgkin lymphoma who has an isolated relapse within the CNS?
2 Answers available
What is your preferred third-line therapy for a fit patient with symptomatic, relapsed follicular lymphoma who has failed bendamustine-rituximab and lenalidomide-rituximab?
2 Answers available
For patients with rectal cancer being treated along PROSPECT paradigm, would you extrapolate from the IDEA literature and offer 3 months of CAPOX neoadjuvantly, without adjuvant therapy?
1 Answer available
How would you manage a patient with NLPHL and CKD who relapsed after a long disease free interval (i.e. 7 years) following bendamustine?
1 Answer available
Would you recommend axillary lymph node dissection in a pre-menopausal woman with ER+ PR+ HER2- IDC, s/p lumpectomy and SLN with pT1c pN1 cM0 disease, where 2 sentinel nodes are positive for macrometastasis and 1 SN is positive for micrometastasis?
1 Answer available
How do you explain the risks and benefits of palliative radiation therapy to patients with fungating breast masses?
Patients are understandably concerned about the risks and benefits of radiation to an oozing, bleeding, and ulcerated breast.
2 Answers available
How do you approach the initial dosing of carfilzomib for patients with relapsed multiple myeloma?
Is the therapeutic purpose of the proteasome inhibitor to maximize total dosage per week or number of infusions per week?
2 Answers available
What is your approach to adjuvant therapy for an R0, ALK+ resected lung adenocarcinoma with N2 disease?
1 Answer available
How extensive of a workup do you do for systemic AL amyloidosis for a patient with a resected amyloidoma, localized AL amyloid deposition in their airway or lungs, who has no other symptoms?
Would you do a 24-hour urine and echocardiogram in all of these patients? Cardiac biomarkers, PT/PTT, or any other such blood tests?
3 Answers available
In patients who have received neoadjuvant endocrine therapy for localized ER/PR+, HER2 negative breast cancer, how do you decide which patients to offer adjuvant chemotherapy to?
What type of adjuvant chemotherapy would you offer? Would clinically positive lymph nodes or residual disease at the time of surgery change your decis...
1 Answer available
Do you give systemic therapy for triple negative breast cancer with brain metastasis and no other sites of disease?
Following SRS to the brain lesions, is it safe to closely follow the patient for recurrence?
4 Answers available
For a patient with triple-class-refractory myeloma and cytopenias who has been collected for CAR-T, would you choose aggressive chemotherapy or a bispecific antibody for bridging?
This question seems quite specific but happens quite often. Multi-drug chemotherapy runs the risk of profound cytopenias and infections, while bispeci...
2 Answers available
What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?
1 Answer available
When will you recommend enfortumab vedotin plus pembrolizumab as first-line treatment of metastatic urothelial carcinoma for cisplatin-ineligible patients?
Will you use it rather than a carboplatin-containing regimen?
2 Answers available
Would you still obtain Ki-67 prior to use of adjuvant abemaciclib in a patient who has otherwise met MonarchE treatment criteria, such as 1-3 positive LNs, grade 3 and/or tumor >5 cm?
Patient is pre-menopausal and has cT3cN1, grade 2, ER positive, Her 2 negative IDC. Metastatic disease to axillary LNs was biopsy-proven. Patient was ...
1 Answer available
With the CANOVA results in mind, would you continue using venetoclax in patients with multiple myeloma with t(11;14)?
1 Answer available
What is your approach to mitigating the infection risk with bispecific antibodies in multiple myeloma?
4 Answers available
Do you ever consider local therapy to oligometastatic hormone-receptor positive breast cancer?
6 Answers available
Will you recommend abemaciclib in combination with standard adjuvant endocrine therapy in patients with high risk hormone receptor positive, HER2- early breast cancer?
With the recent announcement that the phase 3 MonarchE trial met its primary endpoint. 
3 Answers available
How do you choose between the different recently approved Bispecifics Antibodies for Relapsed/Refractory Multiple Myeloma?
I.e. dosing regimen frequency, side effect profile, duration of follow up, etc.
3 Answers available
How would you treat a BTKi naive p53 mutated MCL in 1st relapse with disease noted both systemically and in the CNS?
1 Answer available
For patients who require aggressive debulking in multiple myeloma, what is your preferred chemotherapy regimen and why?
Modified HyperCVAD? V(R)D-PACE? DCEP? Are there any data to favor one over the other?
2 Answers available
How do you manage IgM related peripheral neuropathy?
Do you utilize rituximab or any other specific management strategies?
2 Answers available
What is your preferred adjuvant chemotherapy regimen for a patient with local recurrence of TNBC two years after completing neoadjuvant ddAC-T who declined prior adjuvant capecitabine?
Had mastectomy resulting in ypT1cN1a. Post menopausal female with good PS. 
1 Answer available
Would you offer capecitabine re-challenge for a patient with metastatic breast cancer and a history of coronary vasospasm?
If so, under what circumstances?
1 Answer available
Do you prefer cisplatin or carboplatin in combination with nivolumab per CheckMate 816 for patients with resectable NSCLC?
Based on subgroup analysis, do you have a preference for cisplatin over carboplatin? 
1 Answer available
How would you approach BCMA-directed therapy in a patient with myeloma and renal failure on dialysis?
Would you prefer CAR-T or bi-specific or neither? If CAR-T, how do you approach lymphodepletion? 
2 Answers available
For patients with metastatic thymic carcinoma, is there a role for local treatment options such as SBRT for oligoprogressive or oligopersistent disease after systemic therapy?
1 Answer available
How do you approach post-transplant maintenance for patients with high-risk myeloma?
Which PI and at what dosing intervals? Dexamethasone or not? Emory has now published data with VRd consolidation as well as KPd consolidation, while ...
2 Answers available
Do you recommend routinely getting periodic 24-hour urine monoclonal protein study for patients with active multiple myeloma?
If so, why?
4 Answers available
Would you offer adjuvant capecitabine to a patient with resected intrahepatic cholangiocarcinoma after being treated with neoadjuvant GAP chemotherapy?
4 months of Neoadjuvant GAP resulted in conversion from unresectable to resectable. 
1 Answer available
Do you consider an ovarian cancer patient who progresses on PARP inhibitor, either for treatment or maintenance, to be platinum resistant regardless of time since last platinum based chemotherapy?
Does the exact time since last platinum-based chemotherapy change your answer?
1 Answer available
Would you implement CAR-T therapy earlier in practice if approved in earlier lines for multiple myeloma based on the KarMMa-3 and CARTITUTUDE-4 studies?
3 Answers available
How would you approach treatment for a R/R mantle cell lymphoma patient with a history of autoimmune hepatitis who has progressed on both a covalent and non-covalent BTKi?
1 Answer available
Is there any scenario where you would consider treating a relapsed AYA patient with Hodgkin Lymphoma without consolidative auto transplant?
If so, what treatment regimen would you recommend?
1 Answer available
Do you routinely obtain next generation sequencing for patients with metastatic renal cell carcinoma and if so, what is your approach to incorporating these results into treatment decision making?
1 Answer available
Would you recommend olaparib for a patient with germline BRCA1 mutation and HER2+ metastatic breast cancer who has progressed through multiple lines of HER2-directed therapy including trastuzumab deruxtecan?
Does your approach differ across the HER2 IHC spectrum?
4 Answers available
What is your approach to systemic treatment of de novo metastatic hormone-sensitive prostate ductal adenocarcinoma with lung only metastases?
1 Answer available
What systemic therapy do you recommend for prostate cancer pelvic nodal recurrence on PSMA PET-CT after prostatectomy and salvage radiation?
If ADT +/- ARPI + RT, what duration of systemic therapy do you recommend?
1 Answer available
Do you always start treatment for patients who meet diagnostic criteria for multiple myeloma by SLiM criteria alone?
i.e., 60+% bone marrow plasmacytosis, light chain ratio >100, and/or >1 MRI lesion
2 Answers available
Would you offer adjuvant abemaciclib plus endocrine therapy for favorable histology ER+/PR+/HER2-negative tumors such as pure tubular, mucinous, cribriform, or papillary that otherwise meet MonarchE trial criteria?
MonarchE trial criteria includes "patients with four or more positive nodes, or one to three nodes and either tumor size ≥ 5 cm, histologic grade 3...
2 Answers available
Do you change treatment for confirmed biochemical progression in patients with otherwise secretory MM even if the M-spike is <0.5 g/dL?
3 Answers available
How would you approach therapy for a patient with newly diagnosed non-GC DLBCL with previous anthracycline exposure?
240-300 mg/m2 prior exposure. How would your management change in young fit/older individuals with comorbidities? Would you obtain interval TTE during...
2 Answers available
How do you approach imaging in patients with M0 castration-resistant prostate cancer with rising PSA on an ARSI?
What imaging modality do you use (conventional, PSMA PET, etc.)? When do you image (ex: a PSA threshold or PSADT)?
1 Answer available
How would you approach therapy for a patient with symptomatic secondary CNS marginal zone lymphoma, but with low-volume systemic disease that would otherwise not warrant therapy?
Would your approach differ for a 30 year old and a 70 year old?
3 Answers available
What adjuvant therapy would you give to a patient with resected pT4bN2M0 MSI-H colon cancer and post-op markedly elevated CEA but no metastatic disease seen on imaging?
1 Answer available
In which situations do you offer ovarian suppression with chemotherapy to prevent the development of premature menopause in premenopausal women with ER negative breast cancer?
Fertility preservation already complete with embryo cryopreservation
1 Answer available
Do you utilize Mammaprint testing to determine whether or not to offer neoadjuvant chemotherapy for high risk ER+ breast cancer?
2 Answers available
In which situations do you consider post-mastectomy radiation therapy when the patient has a localized node-positive breast cancer with a complete nodal response and minimal residual disease in the breast post-neoadjuvant chemotherapy?
1 Answer available
What is the role for "liquid biopsy" for patients with newly diagnosed metastatic NSCLC?
5 Answers available
Would you consider adjuvant nivolumab to be the standard of care in stage II/III esophageal/GE junction cancer after completion of neoadjuvant chemoradiotherapy and surgery?
Based on CheckMate 577?Is DFS endpoint sufficient to establish SOC or is OS benefit needed?
4 Answers available
Would you send a lung cancer patient for genetic counseling/germline mutation testing if they are harboring mutations in NGS with variation allele frequency between >=50%?
Ex. TP53, BRCA, T790M, or another? As of now, T790M mutation is one of the few de novo mutations found in treatment naïve patients that have been...
4 Answers available
What is your approach to curative-intent therapy for a young, fit patient with newly-diagnosed monomorphic epitheliotropic intestinal T cell lymphoma (MEITL)?
Do you incorporate PEG-asparaginase or brentuximab vedotin (for CD30-expressing malignant cells) into anthracycline-based induction regimens? Do you c...
1 Answer available
Should high-dose methotrexate be used in the treatment of AYA patients with osteosarcoma?
2 Answers available
In light of the TRIANGLE data at ASH, how should we now approach a transplant-eligible patient with a new diagnosis of aggressive mantle cell lymphoma?
2 Answers available
How would you manage a transplant-eligible patient with DLBCL who relapsed 6-12 months following a CR1 to R-CHOP and then attained a CR2 to platinum-based salvage chemoimmunotherapy?
How do you choose between CAR-T and autoSCT, for example? 
3 Answers available
How would you treat a fit patient with a history of relapsed CLL who now presents with Richter transformation s/p autologous anti-CD19 chimeric antigen receptor (CAR) T-cells?
1 Answer available
In which clinical situations, if any, would you use imiquimod for treatment of breast cancer skin metastases?
1 Answer available
Is there still a role for plasma exchange/PLEX for confirmed or suspected cast nephropathy in multiple myeloma to rapidly reduce light chain burden?
In addition to reversing hypercalcemia, initiating myeloma therapy, etc.
1 Answer available
In light of the recent rEECur trial interim analysis, would you offer high-dose ifosfamide to an AYA patient with relapsed Ewing's sarcoma who initially had a complete response to up-front therapy?
J Clin Oncol 40, 2022 (suppl 17; abstr LBA2). https://meetings.asco.org/abstracts-presentations/209024
2 Answers available
How would you approach therapy for a transplant-eligible patient with peripheral T cell lymphoma NOS who experiences early relapse after CHOEP, but achieves remission to salvage therapy?
Would you still go to auto or consider allo? 
1 Answer available
How would treat a patient with good performance status with PTCL-NOS found to have leptomeningeal disease during treatment course with CHOEP?
Would you intercalate HD-MTX with her CHOEP?
1 Answer available
Would you recommend adjuvant chemotherapy for a patient with subcentimeter pancreatic adenocarcinoma incidentally found during a Whipple resection for high risk IPMN?
1 Answer available
Assuming all options for BCMA-directed therapy are available, how would you approach treatment for a patient with 4 prior lines of myeloma-directed therapy who is eligible for a BCMA-directed therapy?
Ide-cel? Cilta-cel? Teclistamab?
1 Answer available
Did the approval of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) change how you image and manage patients with metastatic castrate-resistant prostate cancer?
When do you order PSMA PET? Do you preferably order Locametz (gallium Ga 68 gozetotide) PET? 
1 Answer available
What is your approach to young healthy women with locally advanced breast cancer and biopsy-proven low cervical lymph nodes?
Would you treat this as a locally advanced breast cancer and offer surgery, radiation, and systemic therapy? Does your management change depending on ...
2 Answers available
For patients with IgG kappa multiple myeloma receiving an IgG kappa mAb (i.e., daratumumab), how important is it clinically to use an interference assay if they're in a VGPR to see if their M-spike might actually be 0?
For example, would you use a tool like the Hydrashift assay? Would this change your management? 
1 Answer available
When you use selinexor for relapsed/refractory myeloma, with what total weekly dose do you practically start?
If tolerated through Cycle #1, how aggressively do you try to titrate the selinexor dose up toward 100mg weekly or 80mg twice-weekly? And does your a...
1 Answer available
What is your approach for using anticoagulation/aspirin in patients with multiple myeloma?
2 Answers available
What is your preferred management for diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH)?
Does your management change if symptomatic or asymptomatic?
1 Answer available
In what circumstances would you stop therapy for patients with metastatic HER2+ breast cancer with long-term complete response to HER2-directed therapy?
2 Answers available
How do you choose between neoadjuvant and adjuvant chemo-immunotherapy for patients with resectable stage II-IIIA NSCLC?
In light of CheckMate 816 and IMpower010 and FDA approval for neoadjuvant chemo-nivolumab and adjuvant chemo-atezolizumab, how do you decide which sys...
2 Answers available
How would you approach adjuvant therapy for a patient with pT2N2 lung adenocarcinoma who underwent an R1 resection and is not amenable to further surgical intervention?
NGS without any actionable mutations and PD-L1 TPS 15%. Would you offer chemotherapy, radiation, or immunotherapy and, if so, in what order?
1 Answer available
For patients with NSCLC on osimertinib who progress, would you continue osimertinib when moving onto chemotherapy for 2nd line therapy?
1 Answer available
Based on results from ADAURA, in clinical practice, how likely are you to recommend adjuvant chemotherapy prior to adjuvant osimertinib for stage IIA T2bN0 EGFR mutant NSCLC?
1 Answer available
What is your preferred up-front treatment for transplant-eligible patients with primary (de novo) plasma cell leukemia?
2 Answers available
What is your approach to pRBC transfusion support for myeloma-related anemia?
How much weight do you give to a hgb/hct threshold versus symptoms?
3 Answers available
What chemotherapy do you use with radiation for urothelial carcinoma with squamous differentiation?
2 Answers available
How do you treat colorectal cancer with heterogeneous loss of mismatch repair protein expression?
1 Answer available
How does your approach to low-risk gestational trophoblastic neoplasia differ for patients whose hCG levels plateau following initial single agent systemic therapy vs those who have a good initial response and then plateau?
1 Answer available
How do you incorporate ctDNA in the management of metastatic breast cancer?
1 Answer available
What are your takeaways from the GPRC5D-Targeted CAR-T trial (Mailankody et al. NEJM Sept 2022) and any key differences compared to the BCMA directed products?
1 Answer available
How would you manage tucatinib-associated grade 2 indirect hyperbilirubinemia in a patient with metastatic HER2-positive breast cancer involving the CNS receiving trastuzumab + capecitabine + tucatinib?
Patient is young. Bilirubin normalizes when tucatinib is held, but again increases to grade 2 when it is restarted. Evaluation for hemolysis was negat...
2 Answers available
How do positive pelvic washings influence your decision to administer adjuvant therapy to early stage endometrial cancer who otherwise meets no criteria for adjuvant therapy?
<60y/o, grade 1 endometrioid endometrial cancer. TLH, BSO, sentinel nodes. Stage IA, focal LVSI, 20% myometrial invasion, negative sentinel nodes, ...
2 Answers available
If you treat a patient with high-risk smoldering myeloma on trial and they develop biochemical progression by M-spike, but still no CRAB-SLiM criteria, what would you do next?
In this case, the patient had received daratumumab/lenalidomide/dexamethasone as part of a cooperative group trial. Would you say that the patient had...
1 Answer available
Is there a role for repeat CAR-T with a potentially different product in relapsed and refractory multiple myeloma?
2 Answers available
How would you manage a CLL patient with Richters transformation that is resistant to R-CHOP with transfusion dependent cytopenias and a marrow demonstrating significant involvement by DLBCL and CLL?
2 Answers available
What is your approach in a fit patient, advanced stage, bulky classical Hodgkin lymphoma who has decreased disease burden in areas but a persistent, hypermetabolic (Deauville 5) anterior mediastinal mass following two cycles of AAVD?
2 Answers available
In terms of contraception, what do you recommend for patients with a history of hormone receptor-negative compared to hormone receptor-positive breast cancer?
1 Answer available
When would you use adjuvant abemaciclib in patients with clinically high-risk ER+, HER2-negative breast cancer, but pCR following neoadjuvant chemotherapy?
Patient is a post-menopausal woman with 4 lymph node mets that was strongly ER+/PR+, HER2-negative invasive ductal carcinoma with a high Ki-67 w...
1 Answer available
How do you approach adjuvant therapy for resected lung adenocarcinoma that was found unexpectedly postop to be N2?
Do you routinely offer post-operative adjuvant radiation in addition to chemotherapy? Are the results of the recently published negative phase II...
10 Answers available
Do you perform a periodic PET CT to screen for extramedullary disease in patients with MM who are in remission?
2 Answers available
Where does Elotuzumab-based combination therapy, specifically EPd, fit in your treatment paradigm for relapsed MM?
Does sequence matter?
1 Answer available
What induction regimen would you choose for a patient with newly diagnosed multiple myeloma with incidental amyloidosis noted on bone marrow biopsy, but with no end-organ damage as a result of amyloid deposition?
Would you consider Dara-CyBorD or a MM triplet/quadruplet such as VRd or Dara-VRd? 
4 Answers available
For patients with KRAS G12C mutated NSCLC, how would you decide between using targeted therapy with sotorasib vs adagrasib?
Is there anything to differentiate the two agents? CNS penetration reportedly with adagrasib, FDA accelerated approval has been given with sotorasib.&...
2 Answers available
Would you consider neoadjuvant endocrine therapy in a postmenopausal patient with ER + locally advanced breast cancer with nodal disease who wants to avoid chemotherapy?
3 Answers available
What is your first line of therapy for refractory Hodgkin lymphoma in an AYA patient?
1 Answer available
How do you approach treatment for a patient with a biochemical relapse while on maintenance lenalidomide after autologous stem cell transplant for multiple myeloma?
What factors (i.e. timing from transplant, dose, prior therapy) impact your decision? 
1 Answer available
How would you approach therapy for a patient with a history of classical HL who achieved a CR to 6 cycles of Brentuximab plus AVD who now presents with widespread non-GC DLBCL?
2 Answers available
How would you approach therapy for BR-refractory Waldenstrom Macroglobulinemia when there is a mixed response to zanabrutinib?
1 Answer available
Outside of a clinical trial, what is your preferred third-line systemic therapy option for a patient with relapsed/refractory ES-SCLC?
1 Answer available
In a life-time non-smoker with stage IV lung adenocarcinoma presenting in visceral crisis, what therapy would you recommend to avoid organ failure while awaiting mutational status?
1 Answer available
What treatment would you recommend in an older patient with multiply relapsed double-hit lymphoma with recurrence following ASCT, pola-BR, and CAR-T therapy?
1 Answer available
How does urinary obstruction impact your choice of therapy for metastatic or locally advanced prostate cancer?
1 Answer available
How do you approach the decision to pursue early versus delayed autologous stem cell transplantation in newly diagnosed multiple myeloma?
1 Answer available
Would you recommend adjuvant chemotherapy for a patient who achieved a CR after TNT for stage III rectal adenocarcinoma but underwent no initial surgery, and now has a local recurrence >12 months later with plans to undergo low-anterior resection?
Total neoadjuvant therapy (TNT) included FOLFOX x 4 months and concurrent chemo-RT
1 Answer available
How would you treat a patient with blastoid mantle cell lymphoma with hepatic involvement causing significantly elevated bilirubin?
1 Answer available
Would you consider giving FLOT entirely in the neoadjuvant setting for resectable gastric cancer?
If so, how many cycles would you give? Both the MAGIC and FLOT trials showed difficulty with administering adjuvant chemotherapy.
2 Answers available
What is the optimal treatment for a fit, elderly patient with NGC diffuse large B cell lymphoma that recurred about 1 year after dose-attenuated R-CHOP?
1 Answer available
How would you treat gray zone lymphoma which initially achieved a CR after 2 cycles of DA-R-EPOCH, but end-of-treatment PET demonstrates progression with new sites of biopsy-proven disease?
1 Answer available
What adjuvant systemic therapy would you recommend for a woman s/p ALND for a nodal recurrence of ER-/HER2+ breast cancer 1 year after completing adjuvant therapy with paclitaxel/trastuzumab for her initial disease?
At initial diagnosis she had T1cN0 disease treated with lumpectomy and SLNB followed by 12 weeks of paclitaxel with 1 year of trastuzumab.
4 Answers available
What is the optimal treatment strategy for patients with stage IV NSCLC who have an actionable molecular target identified after initiation of first-line systemic therapy?
1 Answer available
When would you use PSMA PET over conventional imaging for prostate cancer?
Would you use it for initial staging or at time of biochemical recurrence?
2 Answers available
How do you define cisplatin ineligibility for muscle invasive bladder cancer?
1 Answer available
Do you treat de novo metastatic hormone sensitive prostate cancer presenting with a paraneoplastic syndrome more aggressively?
1 Answer available
How would you approach a young patient with oligometastatic inflammatory triple negative breast cancer with bone only metastases?
Would you consider definitive local therapy (surgery, radiation?) if she achieved a good response to initial systemic therapy?
3 Answers available
What is your preferred adjuvant therapy for a patient with triple negative breast cancer and has a BRCA germline mutation who had minimal to no response to neoadjuvant chemotherapy?
Young patient, germline BRCA carrier with cT1cN0 to ypT2N0 disease after docetaxel/ cyclophosphamide x 4.
2 Answers available
In light of ALK-directed therapy, what is the role of chemotherapy for patients with newly diagnosed ALK+ DLBCL?
1 Answer available
In light of ARASENS presented at GU ASCO 2022, how do you approach treatment of de novo metastatic hormone sensitive prostate cancer?
1 Answer available
How do you sequence therapy in an older patient with newly-diagnosed blastoid mantle cell lymphoma with a 17p deletion?
1 Answer available
How would you approach therapy for a patient with smoldering multiple myeloma whose light chain ratio has increased to greater than 100 over several years in the absence of any other myeloma-defining events?
Does a progressing kappa/lambda ratio > 100 at any point in time warrant treatment, or does one wait to treat patients in the setting of a slowly i...
2 Answers available
How would you approach therapy for relapsed/refractory mantle cell lymphoma restricted to the CNS?
1 Answer available
How would you approach therapy for newly diagnosed germinal-center DLBCL who previously received an unknown systemic regimen with radiation for history of Hodgkin Lymphoma?
Would you give R-CHOP without knowing if there was use of prior anthracycline? 
1 Answer available
For a patient with metastatic NSCLC who had progression x2 at a single site treated w RT, would you switch systemic treatment?
Patient has been on pembrolizumab and had two symptomatic soft tissue mass treated with radiation. 
1 Answer available
How would you treat a patient with metastatic RCC who developed posterior reversible encephalopathy syndrome (PRES) on a TKI-containing regimen?
Would you consider re-challenging with a different TKI?
1 Answer available
Do you treat stage 1 non-seminoma differently if there is a component of embryonal carcinoma?
1 Answer available
How would you approach a patient with newly diagnosed hepatocellular carcinoma with very high AFP (>100,000) but no clear radiographic evidence of metastatic disease?
Previously untreated
2 Answers available
Do you offer adjuvant bisphosphonates to high-risk premenopausal women on ovarian suppression for early-stage breast cancer who would want to consider pregnancy in the future?
Which agents would you select and for how long would you treat them?
1 Answer available
How would you approach a patient with imaging and labs suggestive of potentially resectable cholangiocarcinoma when several core biopsies reveal bridging fibrosis with no malignant cells?
1 Answer available
In patients with HCC and asymptomatic but endoscopically visible varices, how long do you wait to start bevacizumab after banding?
1 Answer available
In which situations do you offer neoadjuvant chemotherapy for a nodal recurrence alone of ER/PR positive, HER2 negative breast cancer?
Patient is young and reoccurrence is one year after initial diagnosis of T1cN0 ER/PR positive, HER2-negative breast cancer treated with mastectomy, bu...
1 Answer available
For relapsed/refractory myeloma, how long of a disease-free interval from first autologous transplant do you recommend before considering a second autologous transplant?
1 Answer available
For patients with mild CKD, how do you decide between zoledronic acid and denosumab for bone protection in patients with multiple myeloma?
For pts w/ eGFR between 30-60
1 Answer available
What is your experience with using Frailty Index or other geriatric screening in making decisions for elderly patients with multiple myeloma?
Frailty Index per Palumbo et al. PMID 25628469Is it practical to apply in clinics? Have you made decision changes based on it?
2 Answers available
What is your approach to chemoprevention for HR+ DCIS in the ipsilateral breast in a patient who already completed 7 years of an AI for a prior HR+ invasive breast cancer?
Patient underwent mastectomy for DCIS in the setting of previous lumpectomy and adjuvant radiation for the invasive breast cancer. 
2 Answers available
In what clinical scenarios do you utilize venetoclax-based therapy in relapsed/refractory multiple myeloma?
Venetoclax has demonstrated efficacy in patients harboring t(11;14) mutations but is not FDA approved for MM. Can you expand on what situations you ma...
3 Answers available
What is your preferred first line treatment option for a fit patient with non-squamous NSCLC who is PDL1 positive (1-49%) with no driver mutations?
Does the 2020 approval of Nivolumab and Ipilimumab for mNSCLC with PDL1 >1% impact your decision?
3 Answers available
For metastatic prostate cancer, when would you add carboplatin to docetaxel or cabazitaxel?
1 Answer available
In which cases would you use adjuvant abemaciclib for a patient with extensive residual disease that is triple-positive (ER+PR+HER2+) following neoadjuvant TCHP?
Patient is ypT2N1
1 Answer available
Which systemic therapy (if any) do you offer premenopausal women with a second TNBC local resectable recurrence and an extensive chemotherapy history?
Patient has already received neo/adjuvant treatment with AC, paclitaxel, capecitabine, docetaxel, and carboplatin.
1 Answer available
How would you approach systemic therapy for a pre-menopausal woman with ER+/PR+/HER2 positive breast cancer who had a local recurrence 6 months after completing adjuvant TCH and a year of trastuzumab + tamoxifen?
Would you consider neoadjuvant or adjuvant treatment and if so, which therapies? Patient initially had pT2N0 disease and recurrent disease is also ER+...
1 Answer available
How would you approach systemic therapy for a young post-menopausal woman with locoregional TNBC chest wall recurrence treated with definitive radiation?
Patient previously received neoadjuvant ddAC-T with residual disease at surgery, followed by adjuvant capecitabine which was completed 2 months prior ...
1 Answer available
How would you approach adjuvant therapy for a patient with resected T4N1 high grade large cell neuroendocrine tumor of the cecum with adenocarcinoma component?
Pathology details: 75% high grade large cell neuroendocrine tumor of the cecum (20-30 mitoses per 10 hpf, Ki67 75%) and 25% adenocarcinoma. Patient ha...
1 Answer available
How do you approach patients with recurrent grade 3+ neutropenia on IMiD-containing regimens (e.g., VRd or KRd) beyond dose reductions?
For example: shorten IMiD duration each cycle, add scheduled G-CSF, add antibacterial prophylaxis, etc.
1 Answer available
What infectious prophylaxis do you use for patients with newly diagnosed multiple myeloma?
How do you decide how long to continue?
1 Answer available
What treatment would you consider for small cell neuroendocrine carcinoma of the bladder with a metastatic recurrence within 3 months of neoadjuvant cisplatin/etoposide followed by radical cystectomy (ypT0N0)?
NGS of TURBT specimen had high TMB (18 Muts/Mb).
2 Answers available
How do you manage patients with oligometastatic renal cell carcinoma after nephrectomy and metastatectomy?
Do you observe, offer adjuvant pembrolizumab, or give a first-line metastatic regimen (IO/IO or IO/TKI)? Does your recommendation vary based on risk c...
1 Answer available
Would you offer adjuvant abemaciclib + an aromatase inhibitor to a patient with a local HR+HER- breast cancer reoccurrence while on tamoxifen that meets high-risk criteria?
High-risk criteria meaning >4 positive nodes and Ki67 >20%
3 Answers available
What is your treatment of choice for triple class refractory multiple myeloma?
CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?
2 Answers available
How does one interpret persistently positive lambda light chains on serum immunofixation but without measurable serum monoclonal protein and a normal light chains and ratio?
Is a repeatedly abnormal serum immunofixation all it takes for MGUS?
2 Answers available
Are there effective adjunct therapies to relieve tumor flare pain from tamoxifen in the metastatic setting?
1 Answer available
Which patients with smoldering myeloma do you treat?
2 Answers available
How would you manage asymptomatic radiographic progression from M0 CRPC to M1 CRPC to bone?
PSA rose from 25 to 30 ng/mL over 6 months on darolutamide for M0 CRPC, prompting scans which showed oligometastatic disease to bone, not amenable to ...
1 Answer available
How would one alter therapy in a transplant-ineligible AL amyloidosis with less than a complete response to six cycles of Dara-CyBorD?
Would you continue with daratumumab maintenance per ANDROMEDA or switch regimen?
2 Answers available
What is the optimal prophylaxis regimen to use prior to a selinexor based regimen in the treatment of multiple myeloma for nausea and electrolyte abnormalities? 
2 Answers available
How would you manage an asymptomatic elderly frail patient with newly diagnosed mantle cell lymphoma with TP53 mutation?
Ki67  = 90% with multiple small nodes on PET scan and normal CBC
1 Answer available
How would you approach a patient with mediastinal-only recurrence of small cell lung cancer < 6 months after primary surgical resection and adjuvant platinum-etoposide for Stage I disease?
1 Answer available
How would you manage a patient with history of follicular lymphoma treated with Bendamustine-Rituximab who now has a new FDG avid lesion that is biopsy proven CD30 positive CD20 negative DLBCL?
2 Answers available
Would you consider hormone replacement therapy in young women with germline BRCA1 mutation and history of triple negative breast cancer who underwent bilateral mastectomy and prophylactic bilateral salpingo-oophorectomy?
This situation can feel uncomfortable.  Would this feel safer if patient is s/p mastectomy and had TNBC?
1 Answer available
For metastatic clear cell RCC, would you consider cabozantinib + nivolumab after progression on first line ipilimumab + nivolumab?
Or what is your preferred regimen for stage IV ccRCC following progression on IO/IO?
4 Answers available
How would you manage metastatic small cell/neuroendocrine bladder cancer after response to 6 cycles of platinum/etoposide?
If any clinical benefit (ie. CR, PR or SD) would you consider switch maintenance avelumab, surveillance until progression, or an alternate regimen?
1 Answer available
What treatment would you consider for metastatic urachal carcinoma following progression on FOLFOX and FOLFIRI?
Molecular profiling revealed no targetable alterations, however tumor mutational burden was >10 mut/Mb.
1 Answer available
What's the optimal management of stage IA nodal ATLL in a young fit patient?
Patient in mid-30s with no major medical history presented with isolated left neck swelling. Incisional biopsy w/ HTLV1/2 associated ATLL, Ki67 of >...
1 Answer available
How would you manage adjuvant treatment of a premenopausal woman with HER2 positive, ER/PR negative multifocal micro-invasive node-negative breast cancer?
Largest invasive focus is 0.4mm
1 Answer available
How do you approach a patient with an anaplastic plasmacytoma without systemic evidence of disease in the bone marrow?
What about multiple anaplastic plasmacytoma without bone marrow involvement?
2 Answers available
What is your preferred regimen for metastatic clear cell RCC following progression on IO/TKI?
Patient has progression of liver metastases while on pembrolzumab/axitinib. ECOG PS 1 and limited comorbidities.
3 Answers available
What is your approach to the treatment of metastatic renal cell carcinoma with unclassified histology?
1 Answer available
For a young patient who had a prior pCR to neoadjuvant therapy, would you consider systemic therapy after local resection and radiation of an isolated brain metastatic recurrence of triple negative breast cancer?
CNS recurrence occurred within two years of prior neoadjuvant therapy
1 Answer available
How are you choosing between ipilimumab/nivolumab versus platinum/pemetrexed for unresectable epithelioid mesotheliomas?
2 Answers available
Would you recommend surgery or radiation for newly diagnosed localized prostate cancer diagnosed on a urethral lesion biopsy?
GS 4+4. PSA low (1-2). CT and bone scan negative for lymphadenopathy or metastatic disease.  Prostate MRI pending. 
2 Answers available
Do you continue bortezomib past 8 cycles for transplant ineligible patients with multiple myeloma on VRd who are tolerating therapy well with no neuropathy?
Would you use MRD status to guide your decision making? 
1 Answer available
Would you move to a venetoclax-based regimen for a patient with pentarefractory MM and t(11;14) translocation, previously treated with bortezomib and carfilzomib?
If so, venetoclax/dexamethasone by itself or do you include a PI?
2 Answers available
For a young patient with small cell bladder cancer, what would you recommend following cisplatin + etoposide, if scans show no evidence of distant disease and repeat TURBT shows no malignancy?
2 Answers available
Do you prefer carboplatin or cisplatin with etoposide for stage IV extra-pulmonary neuroendocrine carcinomas with a Ki-67 > 55%?
1 Answer available
Which chemotherapy regimen would you recommend for locally recurrent TNBC several years after therapy with docetaxel + cyclophosphamide for four cycles?
1 Answer available
For locally advanced rectal cancer, would you consider utilizing the RAPIDO trial approach of short course radiation followed by neoadjuvant chemotherapy prior to surgery?
Colleagues in surgery have raised concerns about post radiation effects in the pelvis with the ordering of short course RT->chemo ->surgery.
5 Answers available
For patients with metastatic triple negative breast cancer on nab-paclitaxel + atezolizumab who have an ongoing response, are you continuing immunotherapy after the FDA withdrawal of atezolizumab?
1 Answer available
What is your preferred maintenance strategy for high risk multiple myeloma?
2 Answers available
When do you add an adjuvant bone-modifying agent in patients with history of localized breast cancer?
Is there any role for denosumab? How do you counsel patients regarding the benefit of bisphosphonates on breast cancer outcomes?
3 Answers available
Would you treat a postmenopausal women with high grade T2N0 ER-, PR+, HER2- invasive ductal carcinoma with upfront surgery or neoadjuvant chemotherapy?
ER <1%; PR 45%, Her2 negative by IHC and FISH. Grade 3, Ki67: 80%.
1 Answer available
How do you manage HR+HER2 negative ILC metastatic recurrence in a post-menopausal woman with extensive GI involvement complicated by a small bowel obstruction?
Patient was on tamoxifen when progression occurred; unable to tolerate adjuvant AI.
1 Answer available
In light of RxPonder results for postmenopausal women with early stage node positive HR+HER2- breast cancer, when is there a role for full axillary LN dissection to confirm degree of nodal involvement and when would sentinel LN evaluation be sufficient?
How would this affect adjuvant radiation plan in breast conservation therapy patients and mastectomy patients?
1 Answer available
What is your preferred treatment for Stage IIA seminoma or IIB seminoma with LN <3 cm and normal tumor markers after orchiectomy?
Does patient age effect your approach? Would you consider RPLND for any patients in light of the phase II SEMS trial presented at the 2021 ASCO GU Ca...
3 Answers available
How would you manage asymptomatic brain metastases from testicular non-seminomatous germ cell tumor with a choriocarcinomatous component?
2 Answers available
How does age factor into your planning whether to give a high risk pre-menopausal patient with breast cancer ovarian function suppression?
Do you have a specific age cutoff?
2 Answers available
Would you consider surgical management of a TNBC primary after a patient has had radiographic resolution of oligometastatic disease?
Patient with T2N1 disease and isolated liver metastases. Axilla and liver completely responded to chemo + IO, but limited residual breast enhancement ...
2 Answers available
Would you consider PRRT re-treatment in a patient with a well differentiated NET previously treated with 4 cycles of PRRT?
2 Answers available
How and when are you using sipuleucel-T in metastatic prostate cancer given the increase in available treatment options?
Do prior treatments for mHSPC change your thinking on whether or not to use sipuleucel-T?
2 Answers available
Would you give adjuvant therapy for a urothelial carcinoma T2 on TURBT but pTis at margins on cystectomy?
Patient has not had any prior systemic treatment and is cisplatin-eligible.
1 Answer available
Would you offer adjuvant chemotherapy to a young adult with undifferentiated embryonal sarcoma of the liver?
What factors make you more likely to offer or omit chemotherapy?
1 Answer available
What is the role of liver transplant in NET?
3 Answers available
Do you recommend adjuvant treatment for nodal isolated tumor cells in an otherwise low-risk endometrial cancer?
1 Answer available
What is the preferred regimen for AYA patients with T-Cell Lymphoblastic Lymphoma?
1 Answer available
What is the preferred adjuvant therapy for high-risk non-clear cell RCC?
1 Answer available
How would you proceed for a patient with metastatic gastric-type adenocarcinoma, with vaginal and inguinofemoral disease only, who experiences complete response to her vaginal tumor but residual inguinal disease?
History of CDH1 mutation and prophylactic gastrectomy in 2017 - no other primary site found beyond vagina at diagnosis. Vaginal tumor completely resp...
2 Answers available
How would you treat stage II pediatric type follicular lymphoma that is not amenable to surgical resection in an adolescent and young adult patient?
1 Answer available
How would you treat a patient with squamous NSCLC with NRG1 amplification (no fusion) who has progressed on first-line treatment?
Would you consider afatinib? Afatinib has shown some activity in NRG1 fusion + patients but amplifications is unclear. 
2 Answers available
How do you treat patients with newly diagnosed metastatic MiT Family Translocation Renal Cell Carcinoma?
MiT subfamily translocations = TFE3, TFEB, TFC, or MiTF
2 Answers available
Would you consider radical prostatectomy for a young male with unfavorable intermediate risk cT3a prostate cancer and PSMA PET concerning for regional lymph nodes involvement but negative conventional imaging?
Gleason 4+3=7 and PSA 4
3 Answers available
For persistent localized muscle-invasive bladder cancer following chemoradiation in patients who are not surgical candidates, what is an appropriate next therapy?
2 Answers available
Is there evidence that oral contraceptive pills are less effective in pre-menopausal women on tamoxifen chemoprevention?
We usually recommend copper IUDs, but that's not feasible in all women.
1 Answer available
Do you recommend trilaciclib as primary prophylaxis for myelosuppression in certain patients with ES-SCLC treated with first line chemo-immunotherapy?
1 Answer available
How would you manage adjuvant therapy for a premenopausal female with a T1cN1mi breast IDC that is HR+ HER2 positive on biopsy, but HR+ HER2 negative on lumpectomy surgical specimen?
<40y/o female w/ initial biopsy showing G3 IDC with 80% ER+, 90% PR+, and HER2 positive (IHC 2+; 1.6 HER2/CEP17 ratio and 6.3 HER2 copies/nucleus.)...
2 Answers available
What dose of PEG-asparaginase do you recommend for teens with high BMI treated on a pediatric ALL regimen?
Would you plan straight pediatric dosing using 2500 Units/m2 or a cap of 3750 Units as used in some adult ALL regimens due to excess liver/pancreas to...
2 Answers available
How do you approach adjuvant treatment of pT1cN0 metaplastic triple negative breast cancer?
Healthy 67 y/o woman, 1.5cm tumor, grade 3
1 Answer available
Should a teenager diagnosed with CML in blast crisis go to transplant once MRD is negative?
2 Answers available
What treatment regimen would you recommend for young adults with platinum refractory relapsed germ cell tumors?
2 Answers available
How would you adjust therapy for a patient with high risk, stage III choriocarcinoma (lung mets) in the context of renal insufficiency (Cr 3.8)?
1 Answer available
In a patient with metastatic clear cell RCC who achieved a prolonged PR with first line nivolumab/ipilimumab, discontinued due to IRAEs, would you consider a TKI/checkpoint inhibitor combination regimen?
In this case, nivo/ipi discontinued for immune-related arthralgias requiring steroids and an anti-TNFa agent, now off all immunosuppression.
1 Answer available
How do you approach adjuvant therapy for a premenopausal patient with a pathologic BRCA1 mutation whose TNBC had a complete response to neoadjuvant chemotherapy except for an ITC in one LN?
Patient was given ddAC + T
2 Answers available
When would you recommend adjuvant therapy for a patient with urethral adenocarcinoma after partial urethrectomy?
What clinicopathological features would need to be present for you to recommend adjuvant chemotherapy? Would you treat pT3 disease? Any specific histo...
2 Answers available
After completing 6 cycles of docetaxel plus ADT for metastatic hormone-sensitive prostate cancer per CHAARTED, are there clinical scenarios in which you would add an additional AR targeted agent (ex: enzalutamide, abiraterone, or apalutamide) to ADT?
Does post docetaxel PSA influence your decision?
1 Answer available
For persistent PSA elevation after prostatectomy, would you recommend salvage radiation if pathologically negative nodes, but regional and non-regional lymphadenopathy on PSMA PET?
Specifically, would you offer salvage radiation to a patient who underwent a prostatectomy with PLND and had a post-op PSA of 12 with pathology reveal...
2 Answers available
How would you sequence therapies for a patient with chemotherapy-naive metastatic castration-resistant prostate cancer who is MSI-H on tissue-based NGS?
What line would you give pembrolizumab?
1 Answer available
How would you manage a patient with recurrent granulosa tumor following secondary, R0 cytoreduction, and negative inhibins postoperatively?
Primary, R0 debulking in 2019, stage IA. Low volume recurrence, now again optimally cytoreduced. 
1 Answer available
How would you approach a stage 1 HR+/HER2- pre-menopausal patient <50 years old with Oncotype DX RS of 24?
Would you offer this patient chemotherapy? What are your thoughts about OFS plus AI and avoiding chemotherapy?
4 Answers available
After an optimal tertiary cytoreduction for recurrent granulosa cell tumor previously treated with BEP and hormonal therapy, would you recommend systemic chemotherapy?
Initial diagnosis was 15+ years ago
2 Answers available
What adjuvant systemic therapy would you offer to a healthy elderly woman with a 5mm, node negative, grade 2 HR+HER2+ invasive lobular carcinoma?
Would you choose to incorporate HER2-targeting agents, chemotherapy, endocrine therapy, or a mix of these?
4 Answers available
What is the preferred treatment approach for an AYA patient with intermediate to high risk Hodgkin lymphoma: The pediatric approach (ABVE-PC +/- radiation) or the adult approach (ABVD with possible escalation to BEACOPP)?
1 Answer available
What is your approach for endocrine therapy in young women (<35 years old) with HR+/HER2+ breast CA with residual disease after TCHP who will start adjuvant T-DM1?
3 Answers available
What would you recommend as the next line treatment in a post-menopausal woman with hormone receptor positive, HER2 positive breast cancer, with progression on T-DM1 in combination with aromatase inhibitor?
1 Answer available
Which adjuvant chemotherapy regimen would you recommend for a peri-menopausal woman with synchronous stage IA primary breast tumors, one that is ER+HER2+ and the second ER+HER2-?
1 Answer available
Are there circumstances where you would recommend every 6 week dosing schedule for pembrolizumab monotherapy?
I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...
3 Answers available
Should end-of-therapy echocardiograms be obtained for AYA patients with sarcomas who have received high-dose anthracyclines?
At what frequency and for how long should echos be monitored?
1 Answer available
How would you treat/counsel a patient with Stage IB3 SCC of the cervix who is 18 weeks pregnant and desires to maintain pregnancy?
1 Answer available
If neoadjuvant therapy is indicated for luminal A breast cancer, when do you decide to use chemotherapy versus endocrine therapy?
Are there particular patient characteristics (e.g. age, ER%, Ki67, grade) that make you more likely to choose neoadjuvant endocrine therapy?
1 Answer available
How do you manage adjuvant endocrine therapy for pre-menopausal women with locally advanced, weakly positive ER/PR, HER2 negative breast cancer?
Would a pCR to neoadjuvant chemotherapy change your management? (ER <5%, PR <5%)
1 Answer available
For anatomic stage III ER/PR+ breast cancer treated upfront with surgery, how do you decide which adjuvant chemotherapy to offer?
Do features such as nodal involvement, Ki-67, degree of ER positivity, etc. change your management? Would you use any gene expression assays to help y...
1 Answer available
How do you treat a patient with widely metastatic, non T790M mutated, EGFR exon 20 insertion mutated lung cancer?
Are there any data to support a specific TKI therapy for non-T790M exon 20 mutations/insertions?
5 Answers available
How does clinical intramammary lymph node involvement in HER2+ breast cancer affect your neoadjuvant chemotherapy choice?
Would you prefer TCHP over TCH? Would you consider adding an anthracycline?
1 Answer available
How do you manage a HR-/HER2+ breast cancer patient with local progression during neoadjuvant TCHP?
How would you approach additional systemic therapy? Would the clinical stage of the cancer affect your management?
1 Answer available
What is your approach to consolidation for localized small cell bladder cancer after neoadjuvant cisplatin and etoposide?
Specifically, for cT2N0M0 small cell bladder cancer without response to neoadjuvant cisplatin and etoposide on imaging, would you proceed with cystect...
1 Answer available
What is your platelet cutoff for atezolizumab + bevacizumab in HCC in the absence of bleeding (variceal or otherwise)?
1 Answer available
What is your approach to patients with malignant breast adenomyoepithelioma?
Is adjuvant radiation and/or adjuvant chemotherapy indicated? 
1 Answer available
Are there any clinical scenarios where you would recommend adjuvant docetaxel for localized prostate cancer?
1 Answer available
What is your preferred second line therapy for an HCC patient who progressed after first line checkpoint inhibitor monotherapy?
Would you try atezolizumab/bevacizumab or switch to a TKI?
2 Answers available
How do recent RxPonder results affect your adjuvant therapy choice for premenopausal women with HR+/HER2 negative breast cancer with 1-3 positive LNs?
Would you consider an Oncotype or Mammaprint? Would your management change if the patient had 1-3 positive LNs on SLNBx (as opposed to ALND)?
1 Answer available
For a patient on dialysis with metastatic clear cell renal cancer, what regimen would you use after front line immunotherapy?
1 Answer available
When might you recommend adjuvant chemotherapy for fully staged/resected stage IA clear cell ovarian carcinoma?
2 Answers available
What adjuvant therapy do you recommend for comprehensively staged, stage II, FIGO grade 3 deeply invasive endometrial cancer?
1 Answer available
For a patient who is cisplatin-eligible with localized, high-grade upper tract urothelial carcinoma, but no muscularis propria seen on biopsy, what is your approach?
What neoadjuvant or adjuvant therapy would you give?
1 Answer available
How would you manage a clinically inoperable, stage IIIB, MMR deficient uterine cancer?
Tumor felt to be technically unresectable due to extensive cervical/parametrial involvement. ER/PR and HER2 testing are pending.
1 Answer available
In what situations would you offer systemic therapy for HER2+ microinvasive invasive ductal carcinoma?
1 Answer available
What are your recommendations for post-menopausal patients who would fit into RxPonder trial criteria (HR+/HER2- breast cancer, 1-3 positive LNs) and have already started on adjuvant chemotherapy?
Would you send Oncotype during chemotherapy if not sent already? Would you stop adjuvant chemotherapy if a prior Oncotype was 25 or less?
2 Answers available
For patients on a bone-modifying agent for osteoporosis/severe osteopenia in the context of adjuvant AI therapy, how do you manage the bone-modifying agent once their AI course is complete?
1 Answer available
How long should breast cancer patients whose surgeries are delayed due to COVID-19 remain on neoadjuvant endocrine therapy?
For patients with low risk, early stage, HR+/HER2- breast cancer who initiated endocrine therapy in order to delay their surgery due to the COVID 19 e...
3 Answers available
How do you approach adjuvant endocrine therapy in a pre-menopausal patient with node negative HR+HER2- breast cancer with a high Oncotype RS who received adjuvant chemotherapy?
What is your specific therapy choice and duration?
1 Answer available
How do the new RxPONDER results affect your choice of adjuvant therapy for postmenopausal women with HR+/HER2 negative breast cancer and 1-3 positive lymph nodes?
Would you send an Oncotype RS to determine the role of adjuvant chemotherapy and/or endocrine therapy?
1 Answer available
How would you approach adjuvant therapy for a young post-menopausal woman with a grade 3 pT1a (5mm) node negative ER+/HER2- invasive ductal carcinoma?
 Would you consider gene profiling to determine need for chemotherapy?
2 Answers available
How would you manage a middle aged woman with history of severe alcoholic liver cirrhosis and a small node negative ER/PR positive, HER2 negative breast cancer?
How would you balance the competing risks of these two diagnoses in her treatment?
3 Answers available
How would you manage adjuvant treatment of a patient with ER+/PR+/HER2+ breast cancer and a small amount of residual disease (e.g. T1mi) following neoadjuvant TCHP?
Patient had a clinical T2N0 cancer at diagnosis, completed 6 cycles TCHP, and had 0.2mm residual disease with 80% cellularity, negative sentinel node.
4 Answers available
When would you offer ovarian suppression in addition to endocrine therapy for premenopausal women who omit adjuvant chemotherapy?
How do clinical risk and Mammaprint/Oncotype scores affect your decision?
1 Answer available
How will you counsel patients with breast cancer receiving adjuvant chemotherapy regarding COVID-19 vaccine administration?
For example, will you recommend a certain vaccination timing in relationship to their treatment? Any concerns for reduced immune response or risks of ...
1 Answer available
What second line therapy would you use for metastatic clear cell RCC after a 6-12 month response to ipilimumab/nivolumab followed by development of multiple bone metastases but stable soft tissue disease?
Ex: TKI alone, TKI + checkpoint inhibitor, checkpoint inhibitor alone, TKI + mTOR inhibitor. Please specify drug regimen, if applicable.
2 Answers available
When would you consider adjuvant chemotherapy for resected, intermediate grade lung neuroendocrine tumors?
Pathology is not carcinoid or small cell.
1 Answer available
Would you use maintenance avelumab for a patient with metastatic urothelial carcinoma who progressed on first-line pembrolizumab, then had stable disease after at least four cycles of second-line carboplatin plus gemcitabine?
Would it change your decision if they had progressed on a first-line trial with cisplatin followed by pembrolizumab plus enfortumab vedotin maintenanc...
1 Answer available
How would you manage a patient with localized prostate cancer treated with radical prostatectomy and found to have a single involved pelvic lymph node on final pathology and a detectable postoperative PSA?
2 Answers available
How would you approach adjuvant systemic therapy for a patient with a history of localized triple negative breast cancer 7 years prior for which she received adjuvant AC-T, now presenting with another ipsilateral T1cN0 triple negative breast cancer?
Given the data from KEYNOTE-522, would you try to incorporate chemotherapy in the treatment regimen?
2 Answers available
When would you offer anthracycline based adjuvant chemotherapy for a T1cN0 TNBC?
Does tumor size impact your recommendation? High grade? Young patient age?
2 Answers available
For a metastatic neuroendocrine tumor patient who has experienced prolonged progression free survival, how would you approach surgical debulking?
Does the advent of more effective therapies like peptide receptor radioligand therapy (PRRT) and capecitabine and temozolomide (CAPTEM) dampen enthusi...
1 Answer available
How do you manage ovarian suppression for premenopausal patients with HR+/HER2 positive breast cancer?
Does lymph node positivity change your management?
1 Answer available
Would you give immunotherapy to patient with metastatic NSCLC who had liver transplant for hepatocellular carcinoma and now is progressing on chemotherapy?
1 Answer available
How would you manage a premenopausal woman with a poorly differentiated pT2 HR+/HER2- breast cancer and 3/3 SLNs with ITCs?
Would you consider ALND and /or XRT to axilla?
1 Answer available
How would you council a woman in her 50s with Stage I HR+/HER2- breast cancer with a high risk Mammaprint but intermediate OncotypeDx regarding adjuvant chemotherapy?
3 Answers available
Would you use a platinum containing regimen such as docetaxel + carboplatin for an aggressive ER+ breast cancer in a patient with a deleterious mutation in ATM?
1 Answer available
How do you decide to choose TC vs CMF for HER2 negative breast cancer patients who warrant adjuvant chemotherapy?
2 Answers available
Is it acceptable to use TCHP instead of AC-T + trastuzumab as neoadjuvant chemotherapy for HER2+ inflammatory breast cancer?
Patient case is triple positive inflammatory breast cancer
2 Answers available
Would you consider HRT after BSO in a pre-menopausal gBRCA2+ patient who has no intention of ever having prophylactic bilateral mastectomies and who declines chemoprophylaxis?
2 Answers available
How do you manage a young patient with mediastinal nonseminomatous germ cell tumor that has relapsed after primary treatment with four cycles of VIP?
1 Answer available
What is your adjuvant treatment approach to patients with strongly hormone-receptor positive breast cancer who have minimal response to neoadjuvant chemotherapy?
2 Answers available
What is the maximum cumulative anthracycline dose you would administer in a patient with metastatic breast cancer who is asymptomatic with good disease control on liposomal doxorubicin?
2 Answers available
For a patient with isolated CNS recurrence of HR+HER2+ breast cancer after completion of adjuvant therapy, what, if any, systemic therapy would you start after completion of local therapy?
Of note, the patient received cytotoxic plus HER2 directed adjuvant therapy but declined endocrine therapy. 
2 Answers available
How do you decide what induction chemotherapy regimen to use for a patient with locally advanced rectal cancer (cT4N1) receiving total neoadjuvant therapy?
Would you use FOLFIRINOX as in Prodige 23 or FOLFOX as in RAPIDO?
1 Answer available
How do you counsel patients with a curable breast cancer that there is no indication for additional surveillance imaging after treatment other than continuing annual mammograms?
4 Answers available
How would you treat patient with a recurrent thymic carcinoma after prior surgery and concurrent chemoradiation?
Chemoradiation completed 1.5 years prior
1 Answer available
When do you offer adjuvant radiation in addition to chemotherapy for patients with high risk localized gastric adenocarcinoma who did not receive pre-operative therapy?
The patient went straight to gastrectomy for clinical T1 gastric adenocarcinoma, but post-op was up-graded to T4 disease.   Both ARTIST and Inte...
1 Answer available
Are pre-menopausal women on tamoxifen at risk for endometrial cancer?
Pre-menopausal women make progesterone and their menses are typically lighter on tamoxifen because it's a mild endometrial ER stimulant blocking their...
3 Answers available
What systemic therapy would you consider, if any, for an isolated but multifocal CNS recurrence of HER2+ HR negative breast cancer treated with local therapy (>4 lesions treated with resection and SRS)?
Patient completed neoadjuvant therapy with TCH 2 years prior, and has no evidence of disease outside the CNS on PET/CT.
1 Answer available
In patients with inflammatory bowel disease with low rectal cancer with planned proctocolectomy, would you consider creation of a pouch?
1 Answer available
For a post-menopausal patient with a pT2N0 HR+/HER2- breast cancer at surgery after 4 months of neoadjuvant anastrozole with minimal clinical or pathologic response, would you utilize genomic testing to guide decision about adjuvant chemotherapy?
Would you test initial core biopsy (prior to neoadjuvant anastrozole) or surgical specimen? Any preference for Oncotype vs. Mammaprint?
1 Answer available
How would you treat oligometastatic NSCLC (brain and bone) with Non-V600E BRAF mutations?
SRS done to the single brain met, PD-L1 5%,  BRAF G469A mutation
1 Answer available
What changes, if any, would you make to a patient’s endocrine therapy for a patient with DCIS on tamoxifen for risk reduction who develops a new lesion (LCIS) while on tamoxifen?
Would your answer change if the new lesion is ALH/ADH?
2 Answers available
How would you treat a patient with metastatic NSCLC with repeated episodes of CNS brain metastases but otherwise with good systemic disease control on maintenance therapy?
The patient remains without evidence of systemic disease outside of the CNS on serial imaging. Would you continue treating with SRS as lesions appear,...
2 Answers available
In very rapidly progressive/poorly differentiated hepatocellular cancer, would you use the targeted options (sorafenib/lenvatinib) or would you try a traditional cytotoxic regimen?
1 Answer available
When do you add chemotherapy to post-operative RT for thymomas after a R2 resection?
1 Answer available
How do you approach a stage IIIC triple positive IDC, s/p neoadjuvant TCH and P, lumpectomy, and ALND with significant residual disease at the time of surgery?
Would you recommend additional cytotoxic chemotherapy and/or switch her anti-Her therapy to T-DM1?
5 Answers available
How would you treat a metastatic pancreatic cancer patient who develops symptomatic leptomeningeal disease on first line FOLFIRINOX?
1 Answer available
Can fulvestrant cause a tumor flare reaction in hormone receptor positive breast cancer?
1 Answer available
What is your approach to oligometastatic HER2 positive breast cancer, particularly after excellent clinical response in all sites of disease to trastuzumab, pertuzumab, and a taxane?
1 Answer available
Would you assume a diagnosis of metastatic recurrence and initiate therapy for a patient with history of locally advanced NSCLC treated with definitive chemoradiation who develops multiple enlarging lung nodules that are too small to biopsy?
Is there an advantage to early diagnosis and intervention versus observation until the nodules are amenable to percutaneous biopsy?
1 Answer available
In the setting of COVID-19, would you perform a SLNB for a patient incidentally found to have microinvasive ER+ ILC in contralateral prophylactic mastectomy following neoadjuvant chemotherapy for a locally advanced triple positive breast cancer?
2 Answers available
Would you offer adjuvant therapy to a patient who underwent bilateral mastectomies for DCIS and was found to have isolated tumor cells on sentinel node biopsy?
She had had 4 prior biopsies. Would the fact that she received 2 months of neoadjuvant tamoxifen due to COVID change your approach?
1 Answer available
How would you manage a young patient with newly recurrent metastatic triple negative breast cancer less than a year after completing adjuvant chemotherapy and worsening liver function due to intrahepatic disease?
Patient completed adjuvant AC-T 8 months prior to recurrence. BRCA negative, foundation medicine NGS pending. 
2 Answers available
How would you manage a patient who develops pleural and skin metastases shortly after completing neoadjuvant ddAC-T and surgery for a locally advanced triple negative breast cancer?
PD-L1 is low and she has residual neuropathy from neoadjuvant paclitaxel.
5 Answers available
How do you choose first or second-line systemic therapy for fibrolamellar hepatocellular carcinoma?
What are there most evidence-based options?
1 Answer available
What would you use as adjuvant endocrine therapy for a patient who developed an invasive, hormone receptor positive breast cancer while on raloxifene for almost a decade prior?
Out of curiosity, I did tumor testing, and she does not have an activating ESR1 mutation.
1 Answer available
After WBRT, what systemic therapy would you favor for maximal CNS penetrance in a patient with triple negative metastatic breast cancer and multifocal CNS disease?
Is there any evidence for sacituzumab govitecan (IMMU-132) in this situation with progressive systemic disease after prior anthracycline and taxane?
1 Answer available
Would weak PR positivity make you consider adjuvant endocrine therapy for a young pre-menopausal woman with a HER2 positive, ER negative breast cancer?
If yes, would you offer tamoxifen or ovarian suppression plus AI?
1 Answer available
What is your strategy for a patient who develops an enlarging ipsilateral axillary lymph node shortly after undergoing mastectomy and ALND for a pT2N3 ER+/HER2+ right breast cancer?
This patient underwent mastectomy and ALND (10/28 positive lymph nodes). Immediately following axillary LN dissection (and prior to radiation) imaging...
1 Answer available
What is your strategy for ovarian suppression if unable to achieve goal estradiol levels with leuprolide 3.75mg monthly dose?
Data from the SOFT/TEXT trials showed clinical benefit in ovarian suppression + aromatase inhibition for high risk, premenopausal ...
3 Answers available
With the approval of capmatinib, how would you approach a newly diagnosed metastatic NSCLC with MET Exon 14 skipping mutation?
1 Answer available
Do you recommend routine surveillance MRI brain for asymptomatic patients with metastatic HER2+ breast cancer?
1 Answer available
Would you continue pembrolizumab in an asymptomatic metastatic NSCLC patient with high PD-L1, who develops granulomatous mediastinal lymphadenopathy biopsy proven as sarcoid?
1 Answer available
How would you treat a patient with metastatic NSCLC on pembrolizumab with a sustained complete response, now with 2 isolated small liver lesions?
Would you treated with local therapies (RFA or SRS) and continue pembrolizumab or would you move to second line treatment?
1 Answer available
What neoadjuvant therapy would you choose for a post menopausal woman with ER negative, PR positive high grade node negative breast cancer?
Would you consider genomic assays before neoadjuvant chemotherapy? How would you modify your treatment given the COVID-19 pandemic?
5 Answers available
How would you incorporate ctDNA to follow up a patient status post surgical resection of the primary colon adenocarcinoma and omental deposits after 6 months of FOLFOX? 
Would you continue to trend ctDNA to detect early recurrence?
1 Answer available
Would you recommend adjuvant chemotherapy for a stage IIB triple negative apocrine carcinoma? 
What chemotherapy regimen would you recommend? 
2 Answers available
Would you recommend PMRT for a patient with a right breast mastectomy with closest margin less than 0.1cm?
3 Answers available
What would you recommend for an elderly patient (> 80 year old) with resectable pancreatic cancer?
Upfront surgery vs neoadjuvant therapy? And if neoadjuvant therapy, which regimen? Patient has a good PS.
1 Answer available
Would you withhold immunotherapy for ES-SCLC during the COVID-19 pandemic?
What are the risks of infection with COVID-19 if using immunotherapy?  
2 Answers available
Would you choose neoadjuvant endocrine therapy for a low grade, node negative, ER/PR positive, breast cancer given delays in definitive surgery due to the COVID-19 pandemic?
Would your choice vary based on the patient's gender?
1 Answer available
Do you consider neoadjuvant pertuzumab for node negative multifocal HER2+/ER+ IDC without any single focus >2 cm?
2 Answers available
How has COVID-19 altered your recommendations for invasive mediastinal staging for NSCLC?
Should staging and treatment decisions be made based on imaging alone?
2 Answers available
How should our selection for neoadjuvant chemotherapy for breast cancer change in light of COVID-19?
2 Answers available
Are you more inclined to use neoadjuvant endocrine therapy over neoadjuvant chemotherapy or upfront surgery for your ER+HER2- breast cancer patients during the COVID19 pandemic?
Personally, my practice is to guide patients directly to surgery or to do neoadjuvant chemotherapy rather than to do neoadjuvant endocrine therapy, bu...
1 Answer available
How would differing breast cancer receptors between biopsy and surgery affect your treatment recommendations?
For example, if you had a triple positive breast cancer found on breast biopsy and repeat ER/PR/HER2 testing at the time of surgical resection showed ...
1 Answer available
Would you offer trastuzumab + pertuzumab alone for patients with early stage, HER2+ breast cancer for whom TCHP is clearly indicated but who adamantly refuse any cytotoxic therapy?
3 Answers available
Should we consider deferring adjuvant chemotherapy for resected early-stage NSCLC in light of COVID-19?
If so, how long is too long to wait?
1 Answer available
In which group of patients you would send for RNAseq for translocations/fusions that might be missed by NGS in advanced NSCLC?
4 Answers available
Do you recommend chemoradiation following neoadjuvant FOLFIRINOX for resectable pancreatic cancer?
4 Answers available
How long after lumpectomy for DCIS in a premenopausal patient can tamoxifen be started and still retain the benefit?
This patient is interested in conceiving and therefore would like to wait to start the tamoxifen.
1 Answer available
How long do you give maintenance pemetrexed/pembrolizumab in metastatic NSCLC treated with upfront chemoimmunotherapy?
Do you ever consider stopping if stable disease and good tolerance?
3 Answers available
Would you re-introduce bisphosphonate or denosumab in a bone-only metastatic ER+ breast cancer patient with history of osteonecrosis of the jaw?
2 Answers available
Does the use of slow release hormone replacement therapy impact your adjuvant treatment recommendations for a perimenopausal patient with an intermediate Oncotype score?
For example, if a patient had testosterone pellets injected, perhaps making endocrine therapy less efficacious, would that sway you to use chemo?
1 Answer available
Does mucinous histology impact your recommendations for neoadjuvant therapy in a postmenopausal patient with HR+ HER2- breast cancer with multiple positive lymph nodes?
Being that this is a favorable histology would you use Oncotype Dx to help decide on neoadjuvant chemotherapy? Would you recommend neoadjuvant endocri...
1 Answer available
Is there evidence to support the use of definitive CRT in patients with NSCLC in separate ipsilateral lobes and mediastinal lymph node involvement?
Most trials establishing CRT as standard of care for IIIB NSCLC excluded patients with separate ipsilateral lung nodules given that they were categori...
2 Answers available
How would you approach a patient with a new axillary skin lesion with pathology suspecting a metastatic breast cancer, and no other sites of disease noted on PET imaging?
Would you treat this differently than someone who only presents with axillary nodal disease?
1 Answer available
What neoadjuvant strategies do you utilize for initially unresectable biliary tract cancer?
In your experience, what approach has been successful to bridge to surgery?
2 Answers available
When would you consider gemcitabine/cisplatin with Y90 for patients with unresectable intrahepatic cholangiocarcinoma ?
1 Answer available
How do you approach treatment for solitary fibrous tumor with a multifocal pleural-based metastatic recurrence that is surgically inoperable in a patient with good performance status?
How, if any, do you utilize genomic testing to guide systemic therapy?
2 Answers available
How would you approach a patient with metastatic squamous NSCLC that progressed on carbo/paclitaxel/pembro and has a FGFR3 S249C mutation?
Especially if you don't have trials available at the moment. Would you try off-label erdafitinib (given recent data on bladder cancer) or 2nd line ge...
1 Answer available
Would you offer additional therapy for a patient with HR+ breast cancer on AI+OS who is found to have a focus of ovarian metastasis at the time of elective BSO?
Additionally, would the finding of any mutations, such as ESR1, change your recommendation? 
2 Answers available
Do you recommend ovarian suppression in all premenopausal women under age 35 with ER positive breast cancer based on the SOFT/TEXT data, regardless of other risk features?
For example, is this still your approach in women with small tumors or node negative disease?
2 Answers available
Are you routinely using thrombopoietin agonists in patients with hep C and HCC?
If so, for what platelet count threshold and do you have a preference as to which agent?
1 Answer available
How would you approach frontline treatment for a metastatic non-squamous NSCLC patient with MET amplification and a concurrent KRAS mutation?
1 Answer available
Is tamoxifen absolutely contraindicated in pre-menopausal women with Lynch syndrome?
2 Answers available
How do you treat a fit patient with a solitary pulmonary nodule (2cm) which is biopsy-proven small cell lung carcinoma?
PET-CT and Brain MRI are negative for other evidence of disease.
2 Answers available
Would you consider checkpoint inhibitor therapy alone in a patient with metastatic NSCLC with PDL-1 < 1% who is otherwise refusing chemotherapy?
Would nivo + Ipi be appropriate in this situation, especially if high TMB?
4 Answers available
How would you approach frontline treatment of a patient with metastatic non-squamous NSCLC with ERBB2 amplification and PD-L1 > 50%?
In the absence of a frontline clinical trial, would you treat with carboplatin+pemetrexed+pembrolizumab or consider IMPOWER 150 or other?
3 Answers available
How do you advise women who are at high risk for breast cancer and for whom annual screening breast MRIs are recommended regarding the long-term risks of gadolinium contrast?
1 Answer available
How do you proceed if a breast cancer patient has imaging concerning for pulmonary lymphangitic carcinomatosis but no other evidence of metastatic disease?
1 Answer available
Would you offer contralateral prophylactic mastectomy in an older BRCA1 + woman who is getting treated for newly diagnosed BC with mastectomy and SLNB?
Knowing that benefit of contralateral mastectomy is lower in older women who has already manifested BRCA related cancer and 10-20 % mastectomy related...
1 Answer available
How would you approach a patient with grade 1/2 pancreatic neuroendocrine tumor after progressing on octreotide?
What would be the next line of treatment, PRRT, capecitabine and temozolomide or other?
1 Answer available
How would you treat a case of mixed histology NSCLC/SCLC that rapidly progresses following chemoradiation and durvalumab?
In a patient with lung cancer with both NSCLC and SCLC components, would you offer carbo/pem/pembro or carbo/etoposide/atezolizumab? Or any other alte...
2 Answers available
How would you treat a metastatic lung adenocarcinoma with MET exon 14 skip mutation on ctDNA, negative tissue NGS and PD-L1 of >50%?
The NCCN guidelines regard  MET exon 14 skip mutation   as an emerging biomarker but no formal recommendation to start crizotinib. If high P...
1 Answer available
What is your preferred induction chemotherapy for stage IIIA NSCLC squamous and adenocarcinoma?
Is there any advantage of one regimen over the others?
1 Answer available
How would you manage a postmenopausal female with a history of early stage invasive ductal ER+/HER2- breast cancer s/p mastectomy who has a local recurrence of ER+/Her2 - lobular carcinoma while on letrozole?
2 Answers available
Do you skip sentinel lymph node biopsy for women >70 years old with small (< 2cm) HR+ node-negative breast cancer?
Is this new SSO choosing widely guideline being widely adopted and are there any concerns regarding this for clinical practice?
1 Answer available
Would you finish neoadjuvant TC in a postmenopausal stage I TNBC patient who transferred care to your practice after 1 cycle or would you proceed with surgery and finish chemo adjuvantly?
If finished adjuvantly, what would you do -- continue TC or change chemotherapy? 
1 Answer available
Should neoadjuvant chemotherapy be recommended for HER2+, clinically LN- breast cancer measuring 2-3cm?
If yes, would you still recommend dual HER2 directed therapy? After the TRYPHAENA trial, neoadjuvant therapy with dual HER2 directed therapy has beco...
2 Answers available
How would you approach adjuvant chemotherapy and radiation options in a patient with locally advanced TNBC and Diamond-Blackfan Anemia s/p lumpectomy?
Given that DBA is associated with increased incidence of MDS, AML and other solid tumors, would this modify your treatment recommendations?
1 Answer available
How would you manage a patient with newly diagnosed synchronous triple positive and metaplastic triple negative breast cancers?
For early stage disease in a single breast, would you consider neoadjuvant chemotherapy or upfront surgical staging followed by adjuvant therapy? What...
2 Answers available
How would you approach a patient with Stage III EGFR+ NSCLC who develops oligometastatic disease while on consolidation durvalumab?
Given the potential high risk of developing pneumonitis with TKI post checkpoint inhibitor, do you avoid TKIs and try a different regimen (ex carbo/pa...
1 Answer available
Is there a role for incorporating local therapy into the management of oligometastatic EGFR-mutant NSCLC with curative intent?
If so, what is your approach to sequencing and timing of targeted therapy and local therapy?
1 Answer available
How would you manage a patient with synchronous breast and ovarian cancer, s/p neoadjuvant chemotherapy and surgery for ER+/HER2- breast cancer and found to have an ER+ ovarian cancer nodal metastases at TAH/BSO?
RP node with treatment related changes and surgical specimen from TAH/BSO no other foci of malignancy found. 
1 Answer available
How long do you give neoadjuvant therapy in resectable/borderline resectable pancreatic cancer, when you are considering chemoradiotherapy as part of your neoadjuvant strategy?
I have seen anywhere from 4-6 months utilized.  Is there any data to guide your strategy?
1 Answer available
Will you consider additional capecitabine in a patient with TNBC, residual disease after neo-adjuvant chemo, before getting adjuvant pembrolizumab or placebo on SWOG 1418 clinical trial?
3 Answers available
In light of recent data from ASCO 2019 and the NEJM, would you recommend induction chemotherapy or an adjuvant approach in combination with chemoradiation for locally advanced nasopharyngeal carcinoma?
Does your approach differ by EBV status?  
1 Answer available
What systemic therapy would you offer a postmenopausal women with oligometastatic sternal disease which developed while on tamoxifen?
Provided the sternal lesion was low volume and treated with curative intent and patient has been on tamoxifen for < 5 years, would you switch to AI...
1 Answer available
Do you recommend switching from chemotherapy to AI+CDK4/6 inhibitor after resolution of visceral crisis in a patient with HR+, HER2- metastatic breast cancer?
If so, after how many cycles of chemotherapy would you switch?
5 Answers available
Do you offer neoadjuvant therapy to a postmenopausal cT1cN0 , HER2+, ER/PR+ breast IDC or recommend surgery first?
4 Answers available
In what circumstances, if any, do you administer concurrent capecitabine with radiation therapy in the treatment of breast cancer?
1 Answer available
For patients with HER2+ breast cancer with a resectable HER2+ local relapse within 12 months of completion of standard adjuvant therapy including 1 year of trastuzumab, what adjuvant therapy would you recommend?
Does hormone receptor status impact your decision?
2 Answers available
Do you consider omitting adjuvant radiation therapy in an older patient with node positive TNBC who achieve pCR to neoadjuvant chemotherapy?
2 Answers available
How do you manage patients with HER2 positive breast cancer who have progressive CNS metastases after prior exposure to pertuzumab, trastuzumab, TDM1, and lapatinib?
1 Answer available
Should breast cancer patients with never-treated latent TB and for whom chemotherapy is indicated be treated for latent TB during chemotherapy?
2 Answers available
Would you consider giving tamoxifen prophylaxis to young women with pathogenic BRCA2 muations who are <35 years old?
Tamoxifen prophylaxis has not been studied in women <35 years old, but it would be reasonable to assume they would benefit.
1 Answer available
What systemic therapy would you offer to a postmenopausal patient with an unresectable local recurrence of HER2+/ER weakly + IDC?
In a patient with who had undergone neoadjuvant TCH-P, lumpectomy, and RT and is currently on AI, pertuzumab, and trastuzumab, how do you think about ...
1 Answer available
For patients with EGFR-mutant NSCLC who progress on osimertinib, do you repeat tumor molecular profiling?
If so do you favor repeat tumor biopsy or cfDNA?
2 Answers available
What is the most appropriate adjuvant chemotherapy regimen for pre-menopausal, pT1bN0, TNBC?
Would you forego anthracycline?
1 Answer available
Do you offer consolidation chemotherapy prior to durvalumab in locally advanced, unresectable NSCLC?
In clinical practice, consolidation chemotherapy is sometimes used, though this was not implemented in the PACIFIC trial.Antonia et al., PMID 28885881...
3 Answers available
For ER+ breast cancers that are clinical Stage IIB (T2N1) nearing locally advanced stages, what criteria do you use to determine if you would offer neoadjuvant chemotherapy?
3 Answers available
Would you use CTS5 to help you decide whether to offer prolonged adjuvant ET to HR+ breast cancer?
1 Answer available
What would be your next line of therapy for a postmenopausal metastatic ER+/Her 2- BC, s/p anastrazole and palbociclib/fulvestrant who has progressive disease and ESR1 mutation on ctDNA?
2 Answers available
After partial mastectomy, would you consider Oncotype for an older male with HR +/Her 2- IDC, T1cN0, Grade 2 disease?
Do you see a role for adjuvant radiation therapy?
1 Answer available
What is the preferred clinical management of hyperglycemia related to alpelisib?
1 Answer available
With the FDA approval of third line pembrolizumab for patients with SCLC, how would you select a candidate for pembrolizumab or nivolumab in the third line management of SCLC?
0 Answers available
If a patient on ovarian suppression with goserelin for ER+HER2- BC achieves post-menopausal-range estradiol levels but does not achieve post-menopausal FSH levels, is she suppressed?
Patient has hot flashes.
2 Answers available
In light of recent data suggesting limited activity of Atezolizumab monotherapy in the 2nd line treatment of ES-SCLC, would you still offer Atezolizumab maintenance following combination chemo-IO in the first line setting?
1 Answer available
Based on new data from ASCO2019, would you consider gefitinib +chemotherapy instead of osimertinib frontline for EGFRm metastatic NSCLC pts?
http://abstracts.asco.org/239/AbstView_239_262655.html
6 Answers available
Would you extrapolate data from PACIFIC trial for unresectable disease to consider consolidation therapy with durvalumab for Stage III NSCLC with single-station N2 disease amenable to lobectomy?
4 Answers available
How would you manage a locally advanced TNBC and a malignant appearing renal mass suspicious for a synchronous renal cell carcinoma?
1 Answer available
In a germline BRCA2 positive pt with NSCLC after chemoIO frontline and taxotere as a second line, would you consider PARP inhibitors?
If so, would you combine them vs monotherapy? Patient ECOG is 1
1 Answer available
Would you offer adjuvant chemotherapy in a patient with extensive LCIS/DCIS s/p mastectomy and multiple positive lymph nodes due to surgical seeding?
 If so, would you treat as node + BC with  anthracycline and taxane regimen or   non-anthracycline regimen (i.e  docetaxel and cyc...
1 Answer available
When do you consider total neoadjuvant therapy (chemotherapy and chemoradiation) for rectal cancer?
1 Answer available
How do you advise patients looking for 2nd opinions while on standard-of-care, first line treatment for metastatic ER+HER2- BC(i.e. a CDK4/6 inhibitor + aromatase inhibitor) to bolster requests for chemotherapy when non indicated?
1 Answer available
How would your treat a pregnant woman (2nd trimester) with multifocal HER2+ ER- early stage breast cancer?
greatest measuring 1.0cm.
1 Answer available
Would you give additional chemotherapy to women with stage III HER2+ breast cancer who have a grossly suboptimal response to neoadjuvant TCHP x6?
Or would you proceed with standard-of-care adjuvant approach for high risk patients?
1 Answer available
Do you continue ovarian suppression for pre-menopausal women with HR+ breast cancer after progression on ovarian suppression + AI + CDK4/6 inhibitor (i.e. when fulvestrant is the appropriate next line of therapy)?
1 Answer available
When would you consider neratinib in a patient with locally advanced HR positive, Her2 positive breast cancer who received one year of trastuzumab and pertuzumab?
1 Answer available
Which patients with metastatic breast cancer should have mastectomy?
1 Answer available
What chemotherapy regimen would you recommend for high risk ER+/Her2- LN negative breast cancer with high genomic risk disease?
I.e. according to Mammaprint test?
1 Answer available
After progression on osimertinib, do you recommend overlapping TKI with 2nd line chemotherapy to avoid accelerated disease progression?
Retrospective data suggest clinically significant disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung canc...
1 Answer available
With the approval of frontline pembrolizumab monotherapy for advanced NSCLC with PD-L1 of 1% or above, how do you select who gets Chemo-IO versus pembro monotherapy if PD-L1 between 1-49%?
1 Answer available
How would you manage an elderly patient with a history of stage I CLL and newly diagnosed metastatic ER+/HER2+ breast cancer?
1 Answer available
How would you treat frontline metastatic ER+HER2- breast cancer with activating PI3K mutations?
1 Answer available
Should GnRH agonist therapy be continued beyond 5 years (along with an aromatase inhibitor) in young pre-menopausal women with high risk breast cancer who continue to have ovarian function at 5 years of endocrine treatment?
1 Answer available
How would you manage DCIS diagnosed in the first trimester of pregnancy?
1 Answer available
Would you perform an oncotype DX in a patient with a 0.5cm ER positive breast cancer with one lymph node positive for macrometastatic disease? 
2 Answers available
How do you manage a newly diagnosed locally advanced ER+/HER2- breast cancer with synchronous diagnosis of metastatic melanoma?
1 Answer available
How do you manage a patient with newly diagnosed stage IIA triple negative breast cancer with a history of renal transplantation on immunosuppressive therapy?
1 Answer available
What is the preferred treatment approach for patients with metastatic phyllodes tumor?
1 Answer available
How will the findings from the study of adjuvant capecitabine in TNBC presented at SABCS 2018 (CIBOMA/2004-01_GEICAM/2003-11) affect standard of care?
1 Answer available
What adjuvant treatment would you use in a pT1miN0M0 ER -/HER2 IDC of the breast after bilateral mastectomies?
Patient did not receive neoadjuvant therapy.
3 Answers available
How would you advise a pre-menopausal, HR-, HER2+ BC with treated brain metastases and NED while on trastuzumab/pertuzumab who wants to conceive?
1 Answer available
When do you recommend broader molecular testing for clinical trials in stage IV NSCLC patients who have negative initial molecular testing for FDA-approved targetable mutations?
0 Answers available
Would you resume durvalumab after several month hiatus due to IO unrelated medical comorbidities that has since resolved?
If it is still within the 12 month period and no disease recurrence?
3 Answers available
When do you consider it too late after breast surgery to offer adjuvant chemotherapy to a patient with high risk non-metastatic breast cancer?
Is there a point at which there may be no benefit? More than 3 months from breast surgery? 6 months? 1 year?
1 Answer available
How would you treat a pregnant woman in the third trimester with locally advanced, hormone receptor positive, HER2 positive breast cancer?
Would you maintain dose density of chemotherapy and use peg-filgrastim prior to delivery of the baby? Would you defer taxane and anti-HER2 therapy unt...
2 Answers available
In which scenarios would you consider adjuvant chemotherapy for a patient with T1a N0 triple negative breast cancer?
If so, what would be the regimen that you would consider and what factors would sway you for or against chemotherapy for such patients?
2 Answers available
How would you treat a patient with EGFR+ oligo-metastatic lung adenocarcinoma status post resection of the primary and metastatic sites?
Would you give adjuvant chemotherapy or start osimertinib?
1 Answer available
What chemotherapy regimen would you recommend to a patient with local regional recurrent ER negative, HER2 positive breast cancer who received TCH more than 5 years ago?
The CALOR trial included patients that could receive HER2-targeted therapy.
1 Answer available
What would you offer as systemic therapy to an elderly woman (age >75 years) with HR negative, HER2 positive, lymph node negative breast cancer whose tumor is 2 cm or less?
1 Answer available
Do you offer pembrolizumab monotherapy or carbo-pemetrexed-pembrolizumab to a patient with Stage IV large cell NSCLC with PD-L1 of 80% and KRAS+STK11 mutation?
Some retrospective data reports that STK11 (AKA LKB1) makes NSCLC resistant to immunotherapy. 
2 Answers available
How would you approach a biopsy proven NSCLC patient with mediastinum negative disease and contralateral suspicious spiculated PET avid nodule without pathologic diagnosis?
No other site of metastatic disease. It is unclear if this situation should be managed as two separate primaries or metastatic disease.
2 Answers available
In a premenopausal woman with low risk, early stage HR-positive breast cancer who is unable to discontinue a strong CYP2D6 inhibitor, do you use still utilize tamoxifen versus an AI with ovarian suppression?
2 Answers available
How do you manage elderly patients with borderline PS and ER+ inflammatory breast cancer without metastasis?
Would you consider neo-adjuvant chemotherapy or treat with endocrine therapy?
1 Answer available
How do you counsel your breast-cancer survivors about weight-loss/dietary modifications?
Do your recommendations differ if patients are pre or postmenopausal given the data?
3 Answers available
Should atezolizumab and nab-paclitaxel now be used in first line therapy for metastatic, triple negative breast cancer?
Have the results from IMpassion130 changed the standard of care?
2 Answers available
In patients who develop a VTE on palbociclib, do you discontinue therapy or continue as long as the patient is receiving adequate anticoagulation therapy?
1 Answer available
Do you use docetaxel interchangeably with paclitaxel in breast cancer?
Does the answer vary based on whether it is neo/adjuvant or metastatic setting?
1 Answer available
What is your approach to adjuvant endocrine therapy in high-risk premenopausal women with ER/PR+ Her2+ breast cancer?
How applicable is the SOFT/TEXT data in this setting ?
4 Answers available
Do you offer adjuvant chemotherapy and/or radiotherapy for patients with resected atypical carcinoid of the lung with positive mediastinal lymph nodes (T3N2M0)?
1 Answer available
Do you routinely offer neo-adjuvant chemotherapy for patient with triple negative metaplastic breast cancer?
2 Answers available
Would you offer upfront osimertinib rather than whole brain irradiation for a patient with stage IV, EGFR exon 19 mutated lung adenocarcinoma who presents with leptomeningeal metastases?
1 Answer available
Would you offer chemotherapy to a patient with an in-breast recurrence less than 2 years after a history of lymph node positive ER+PR+HER2- breast cancer treated with mastectomy and adjuvant hormonal blockade?
1 Answer available
Would you re-challenge patients with an EGFR TKI beyond progression if repeated biopsies show redemostration of a sensitizing mutation (exon 19 deletion) and no other resistance mechanisms?
1 Answer available
Would you offer adjuvant therapy for poorly differentiated adenocarcinoma of the galbladder s/p R0 resection with negative nodes?
Would you offer chemotherapy alone per data from BILCAP or is there any role of radiation?
1 Answer available
What adjuvant systemic therapy do you recommend for a pre-menopausal patient with a localized recurrence of ER+PR+HER2- invasive ductal carcinoma while on adjuvant ovarian suppression with an aromatase inhibitor?
2 Answers available
What is the next step in management following surgical resection of a primary adenoid cystic carcinoma of the lung?
Would you consider radiation and/or chemotherapy?
1 Answer available
Would you consider neoadjuvant endocrine therapy instead of chemotherapy for a pre-menopausal patient with a node-positive, ER+PR+, lobular breast cancer?
Initial pathology additionally yields low Ki-67 and is HER2 negative. 
1 Answer available
Is there a role for checkpoint inhibition in patients with advanced, high PD-L1 expressing, chemotherapy-refractory thymoma?
What if the patient has thymoma-associated myasthenia gravis?
2 Answers available
What would you choose as the second line treatment option for a stage IV EGFR mutant lung adenocarcinoma that has progressed on osimertinib?
Carbo/pemetrexed/pembrolizumab, carbo/pemtrexed without immunotherapy or second line immunotherapy (Nivo, Pem or atezolizumab)?
1 Answer available
Would you offer adjuvant chemotherapy to a patient with T3N0M0 NSCLC if the reason for the T3 stage was due to multiple tumor nodules in the same lobe?
All tumors in this case were <2cm in size.
1 Answer available
Would you add HER2 targeted therapy to adjuvant chemotherapy for a patient with initial breast biopsy showing a ER/PR positive, HER2 negative invasive ductal carcinoma but mastectomy sample showing equivocal Her2 by FISH on initial assay with an alternative probe testing positive?
(HER2/CEP17 ratio <2.0, copy number >4.0 and <6.0 signals/cell)
1 Answer available
How do you manage a patient with multiple similar appearing ground glass opacities (~8-9) on Chest CT where one has been surgically removed and confirmed to be adenocarcinoma in situ?
There is no evidence of disease outside the lung on PET, and the patient is completely asymptomatic with negative EGFR, ALK, ROS1, and BRAF and a PD-L...
1 Answer available
What would be your next line of treatment for NSCLC adenocarcinoma that has recurred after chemoradiation with cis/etoposide?
PD-L1 < 50% and no targetable mutations. Would you use carbo/pemetrexed/pembrolizumab or Nivolumab or pembrolizumab?
1 Answer available
What is your systemic therapy approach to women with isolated local recurrences of hormone-receptor positive breast cancer?
How does the timing of recurrence play into your decision?
1 Answer available
How would you treat metastatic NSCLC in a non-smoker with bone biopsy showing adenocarcinoma of lung origin but inadequate tissue for mutational panel or PD-L1?
Lung primary is inaccessible for biopsy and metastatic sites are only 2 small bone lesions. In a non-smoker, a driver mutation is suspected but would ...
2 Answers available
How would you approach the treatment of resectable NSCLC with a solitary resectable brain metastasis and no other sites of metastasis?
Would you offer adjuvant therapy post resection?
3 Answers available
How do you counsel an early stage breast cancer patient with lupus regarding decisions on radiation?
3 Answers available
Would you recommend 10 years instead of 5 years of tamoxifen in a premenopausal woman with early stage, node negative ER/PR/HER2 positive breast cancer?
Pt is healthy and tolerating Tamoxifen well. 
1 Answer available
How would you treat a patient with a history of ER+ breast cancer over 10 years ago, now presenting with an ER+ loco-regional recurrence while still on Tamoxifen?
In a patient treated over 10 years ago with mastectomy and chemo now with recurrence in the ipislateral axilla, would you offer additional with chemot...
1 Answer available
What is your approach to adjuvant HER-2 directed therapy in a patient who developed cardiotoxicity following neoadjuvant TC-HP?
Can these patients be re-challenged with Herceptin?
6 Answers available
Is it safe and/or necessary to combine osimertinib and carboplatin/paclixel for a patient with stage IV EGFR mutated NSCLC and advanced ovarian carcinoma?
Certainly ovarian cancer will respond to carboplatin and paclitaxel and it sounds like a reasonable chemotherapy to give to a stage IV NSCLC, however ...
1 Answer available
In which patients with stage IV NSCLC and PD-L1 TPS >50% plus concomitant autoimmune disease is it considered safe to give immune checkpoint blockers?
1 Answer available
Would you use 6 months (instead of 12 months) of trastuzumab for locally advanced Her-2 positive breast cancer patients?
Would you do this for ER+ patients? According to the PERSEPHONE trial presented on ASCO 2018, in HER2+, non-metastatic breast cancer, 6 months Hercep...
3 Answers available
Do you use gene expression profiling for premenopausal women with hormone receptor positive breast cancer with 1-3 positive lymph nodes?
2 Answers available
For patients at high risk of breast cancer, do you recommend tomosynthesis over traditional two-view screening mammogram?
1 Answer available
How do you manage a locally advanced hormone receptor-positive invasive ductal carcinoma with neuroendocrine (small cell) features?
If there is no response to neoadjuvant AC -->T, would you offer additional adjuvant chemotherapy?
1 Answer available
For early-stage, HR+ Her2- breast cancers, when do you use OncotypeDx v. Mammaprint?
2 Answers available
What is your approach to women with early-stage hormone responsive breast cancer intolerant of AI's who want to remain on endocrine therapy but have contraindications to tamoxifen?
1 Answer available
Do you routinely check echocardiograms for patients getting HER2 directed therapy for metastatic breast cancer?
If so, how frequently?
5 Answers available
What is the role of neoadjuvant breast radiation in patients with triple negative breast cancer progressing on AC-T?
Pt clinically has inflammatory breast cancer making mastectomy a poor option. 
1 Answer available
What would be your choice of endocrine therapy (if any) for a premenopausal woman with an ER positive 2nd DCIS in ipsilateral breast who has completed 5 years of tamoxifen after lumpectomy of 1st DCIS?
First episode was 10 years ago and patient did not receive XRT. Would you give XRT now? 
1 Answer available
When (if ever) would you use fulvestrant up-front instead of an aromatase inhibitor for ER+ or PR+ metastatic breast cancer?
4 Answers available
What do you do for patients with HR+ inflammatory breast cancer who do not achieve a pCR with neoadjuvant chemotherapy?
Do you offer additional adjuvant chemotherapy, proceed to adjuvant endocrine therapy, or search for a suitable clinical trial?
2 Answers available
How do you approach adjuvant therapy in patients who have a poor clinical response to neoadjuvant endocrine therapy?
No prior chemotherapy.
2 Answers available
How do you counsel a patient with a history of breast cancer regarding use of breast MRI for screening?
Patient does not qualify for breast cancer screening by annual MRI per criteria (IBIS lifetime risk<20%, no known genetic predisposition,...
1 Answer available
How do you decide on the sequence of systemic and local therapy for patients with oligometastatic NSCLC?
When would you favor delivering local therapy (e.g. SBRT) prior to systemic therapy?
1 Answer available
Would you treat a patient with HIV or hepatitis C with an anti-PD-1 agent?
These patients have been largely excluded from these trials.  What if the infection is well controlled?
3 Answers available
How would you treat a patient with a small (<0.5 cm) node negative, grade 3 BRCA1 mutated triple negative breast cancer?
An article (BRCA mutation and outcome in BC. Ellen Copson, et al. Lancet Oncol. 2018) showed G3, BRCA+ breast cancer had poorer prognos...
2 Answers available
Do you pursue testing for ERBB2 mutations in patients with metastatic breast cancer who are clinically HER2-negative by IHC and FISH?
If so, when? Are there certain ERBB2 mutations that would predict response to trastuzumab and/or neratinib? 
1 Answer available
Do you use an alternative dosing regimen for CDK4/6 inhibitor in patient with benign ethnic leukopenia?
Following the dosage guidelines based on absolute neutrophil count may cause the patient to end up receiving lower doses.
1 Answer available
Do you intentionally modify your breast cancer treatment plans for those on chronic immunosuppression to avoid secondary cancers?
This is in regards to the risk of secondary cancers after radiation therapy or cytotoxic chemotherapy (such as anthracyclines) in an immunosuppre...
1 Answer available
In what circumstances would you repeat bio markers (ER, PR, HER2) in a patient with breast cancer who has residual disease after neo-adjuvant chemotherapy?
2 Answers available
Do you send Oncotype or Mammaprint as a predictive tool for patients with high grade (3/3) lymph node negative ER+ breast cancers?
What do you do with low grade (grade 1/3) tumors? In other words, does high grade pathology over rules?
1 Answer available
What regimen would you choose for patients with breast cancer requiring adjuvant chemotherapy whose livelihoods depend on fine dexterity (such as a professional musician)?
Would you use a regimen with lower incidence of neurotoxicity such as CMF or a taxane-based regimen with a low threshold to dose-reduce?
1 Answer available
Would you feel comfortable giving a HER2+ breast cancer patient her next cycle of TCHP (Taxotere + carboplatin + Herceptin + Perjeta) on day 17 of the previous cycle?
Some patients request chemotherapy scheduling adjustments to avoid feeling ill on major holidays. Delaying chemotherapy by a few days isn't of particu...
1 Answer available
What is your preferred non-taxane chemotherapy regimen for early-stage HER2 negative breast cancer patients who develop grade 3/4 neuropathy before completion of taxane-based therapy?
Example case: Patient given neoadjuvant docetaxel + cyclophophamide achieves a partial response after 3 cycles of Taxotere + cyclophosphamide but is u...
1 Answer available
Are Mammaprint and OncotypeDx as useful in stratifying risk in patients with early stage HR+, HER2 negative lobular carcinomas, as in those with ductal carcinomas?
1 Answer available
In the high-risk adjuvant or metastatic setting when you initiate patients on ovarian suppression with the plan to start an AI, what protocol do you follow in terms of rechecking estradiol?
How often will you monitor it? In the setting that patient is morbidly obese, does your strategy change?
2 Answers available
What factors do you consider when you are deciding whether to recommend endocrine therapy for a woman who has had a mastectomy for DCIS for contralateral breast cancer risk reduction?
1 Answer available
Would you prescribe an aromatase inhibitor prophylactically for a post-menopausal woman with a deleterious BRCA2 mutation and a history of DCIS who declines prophylactic mastectomy?
Tamoxifen prophylaxis is FDA-approved, but would you extrapolate from adjuvant/metatastic data for hormone receptor positive breast cancer in post-men...
1 Answer available
Do you use endocrine therapy concurrently or sequentially with radiation therapy in hormone receptor positive breast cancer patients?
In the absence of data demonstrating a clinical benefit for one strategy versus the other, what do you do in practice?  
1 Answer available
Is sentinel lymph node biopsy several weeks after partial mastectomy as reliable as sentinel lymph node biopsy done at the time of partial mastectomy?
2 Answers available
Would you consider localized therapies such as radiofrequency ablation to a lung metastasis or Yttrium-90 for liver metastases for disease control for ER+HER2- breast cancer patients with visceral oligometastatic disease who have progressed on all hormonally-targeted therapies and have chemotherapy as their next standard-of-care systemic treatment option?
1 Answer available
Would you consider exemestane (instead of fulvestrant) in post-menopausal patients with hormone receptor pos, HER2- breast cancer who progress on letrozole or anastrozole?
There is limited data that suggests steroidal AI exemestane could be of some benefit after nonsteroidal AI failure (Lonning PE et al. J Clin Oncol 200...
1 Answer available
Knowing that spread of lobular carcinoma is often more insidious than ductal carcinoma, do you order different staging studies for lobular cancer?
For example, would you order a PET/CT to evaluate for lymphatic or distant metastatic disease?
1 Answer available
How do you manage endocrine therapy for premenopausal women with breast cancer who are heterozygous for factor V Leiden but have no history of thrombosis?
1 Answer available
Should additional molecular testing be performed on triple negative breast cancers up-front to identify potentially targetable mutations (e.g. activating HER2 mutations, homologous recombination repair deficiency assays, etc)?
Does your institution do this routinely?
1 Answer available
In women in whom you suspect chemotherapy-induced amenorrhea and are required to start an AI, what is your strategy with regard to ovarian suppression?
I.e. either for treatment of high-risk disease or intolerance/contraindication to tamoxifen. Will you continue it for the full 5 year course?
1 Answer available
Based on the findings of the CALOR trial, among which group of patients with locoregional recurrence of hormone-receptor positive breast cancer would you treat with chemotherapy?
Do you prefer doing this through a "neoadjuvant" approach vs. post-operatively? CALOR trial
1 Answer available
In which patients will you consider the use of adjuvant pertuzumab for HER2 positive early stage breast cancer?
How does the modest results of the APHINITY trial impact your practice?
1 Answer available
Is there a preferential approach for systemic therapy for triple negative breast cancer patients with leptomeningeal disease?
In a patient with isolated leptomeningeal disease (no systemic disease), would you still recommend systemic therapy?
1 Answer available
When do you suggest ovarian suppression for fertility preservation in premenopausal women receiving neo/adjuvant chemotherapy?
Do you reserve this approach for only women with triple negative breast cancer or all-comers?
1 Answer available
Do you rely on Ki67 as an estimate of proliferation to guide the decision for chemotherapy in premenopausal women with hormonally-driven breast tumors?
Is this in addition to or mutually exclusive from oncotype/mammaprint?
1 Answer available
What is the upper limits of anthracycline dose you are willing to give in a treatment-refractory metastatic breast cancer patient if the patient is responding to salvage weekly adriamycin after progression on multiple prior regimens?
Patient has hormone-refracatory disease, had high visceral burden (pulmonary mets, bone, lymph). Progressed on taxane, xeloda, gemcitabine.  Now ...
1 Answer available
How do you treat HER2-equivocal breast cancer in the neoadjuvant setting?
What would you choose if there is no response to neoadjuvant AC-T? Taxol, THP, TCHP?
1 Answer available
Do you recommend neoadjuvant chemotherapy or induction chemo + chemoRT for borderline resectable pancreatic cancer?
How would the new data presented at ASCO GI 2021 from from Alliance A021501 influence your answer?
3 Answers available
In which patients would you recommend extending adjuvant AI-based therapy beyond 5 years?
2 Answers available
Will you continue anti-estrogen therapy in the setting of initiation of TDM-1 for patients with metastatic ER+/HER2+ breast cancer?
1 Answer available
How does genomic profiling/next-generation sequencing assays influence your treatment recommendations in metastatic breast cancer?
At what point do you send these test, and in what instances do the results influence your treatment recommendations?
1 Answer available
At what point do you prescribe duloxetine for the treatment of AIMS (aromatase inhibitor induced musculoskeletal syndrome)?
2 Answers available
What is the role of platinum agents in the treatment of metastatic breast cancer in patients with BRCA mutations?
2 Answers available
How would you approach the management of a patient with oligometastatic NSCLC characterized by a LUL mass and a solitary adrenal metastasis, assuming a good performance status?
1 Answer available
Would you recommend the SOFT/TEXT adjuvant approach of ovarian suppression/AI in a premenopausal woman with high-risk disease who still desires to have a pregnancy?
1 Answer available
Would you offer adjuvant TKI to patients with Stage III, EGFR-mutant NSCLC after standard chemoradiation?
Would you offer adjuvant TKI following ADAURA data?  Or proceed with durvalumab based on PACIFIC data?
1 Answer available
What is the best management for a local recurrence for a stage I NSCLC treated previously with SBRT?
Should fractionated EBRT be administered or can repeat SBRT be used?
1 Answer available


Papers discussed in this category

International journal of radiation oncology, biology, physics, 2013-03-15
Impact of margin status on local recurrence after mastectomy for ductal carcinoma in situ.
International journal of radiation oncology, biology, physics, 2011-05-01
Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins?
International journal of radiation oncology, biology, physics, 2011-11-01
Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy.
The New England journal of medicine, 2015-03-05
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
N. Engl. J. Med., 2015-01-29
Adjuvant ovarian suppression in premenopausal breast cancer.
Lancet, 2007-05-19
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
The Lancet. Oncology, 2016-12
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.
Nat. Med.,
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-02-01
Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.
Clinical breast cancer, 2006-12
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.
Lancet (London, England), 2009-12-19
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
The Lancet. Oncology, 2014-06
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
The New England journal of medicine, 2012-11-08
Trastuzumab emtansine for HER2-positive advanced breast cancer.
J. Clin. Oncol.,
A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.
European radiology, 2022 May 07
Background parenchymal enhancement in contrast-enhanced MR imaging suggests systemic effects of intrauterine contraceptive devices.
The Cochrane database of systematic reviews, 2020 Dec 21
Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-03-15
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-02-01
Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.
Journal of the National Cancer Institute, 2024 Sep 30
Trends in breast cancer specific death by clinical stage at diagnoses between 2000-2017.
J. Clin. Oncol., 2019 Oct 16
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor–Positive Breast Cancer
N. Engl. J. Med., 2017-07-13
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015-04
Treatment of leptomeningeal carcinomatosis: current challenges and future opportunities.
Am J Case Rep, 2017-02-28
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review.
The New England journal of medicine, 2016-08-25
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Lancet, 2017-09-09
Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09
Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain.
Oncologist, 2007-09-01
How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries.
Journal of the National Cancer Institute, 2006-12-20
Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.
Medicine and science in sports and exercise, 2010-07
American College of Sports Medicine roundtable on exercise guidelines for cancer survivors.
J Clin Oncol, 2016 Feb 20
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.
Curr Breast Cancer Rep, 2016-01-01
Reducing the Risk of Breast Cancer Recurrence: an Evaluation of the Effects and Mechanisms of Diet and Exercise.
Crit Rev Food Sci Nutr, 2018 Apr 19
Meat, eggs, full-fat dairy, and nutritional boogeymen: Does the way in which animals are raised affect health differently in humans?
JAMA, 2018-02-20
Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The DIETFITS Randomized Clinical Trial.
JAMA Oncol,
Prolonged Nightly Fasting and Breast Cancer Prognosis.
The New England journal of medicine, 2012-08-02
Combination anastrozole and fulvestrant in metastatic breast cancer.
Lancet (London, England), 2016-12-17
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-09-01
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Breast cancer research and treatment, 2012-11
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.
N Engl J Med,
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
British journal of clinical pharmacology, 2016-06
Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.
The New England journal of medicine, 2014-07-10
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-01
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
Fertility and sterility, 2016-03
Menses resumption after cancer treatment-induced amenorrhea occurs early or not at all.
Breast Cancer, 2017-09-01
Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer.
Journal of the National Cancer Institute, 2010-07-07
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.
J Natl Cancer Inst, 2006 Jul 5
Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
J. Natl. Cancer Inst., 2010-07-07
Tamoxifen and the factor V Leiden mutation.
J. Clin. Oncol., 2003-10-01
Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer.
Breast Cancer Res. Treat., 2005-01-01
The sentinel node biopsy after previous breast surgery: preliminary results on 543 patients treated at the European Institute of Oncology.
Breast, 2016-12-01
Impact of previous surgery on sentinel lymph node mapping: Hybrid SPECT/CT before and after a unilateral diagnostic breast excision.
Zhonghua Zhong Liu Za Zhi, 2016-07-01
[Feasibility analysis of sentinel lymph node biopsy in patients with breast cancer after local lumpectomy].
Breast, 2016-08-01
Evaluation of sentinel lymph node biopsy after previous breast surgery for breast cancer: GATA study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Cancer, 2010-11-15
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.
The breast journal, 2017-11
An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.
The New England journal of medicine, 2011-06-23
Exemestane for breast-cancer prevention in postmenopausal women.
Lancet (London, England), 2016-02-27
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Cancer investigation, 2011-11
The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-12-01
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.
Cancer Treat. Rev., 2011-10-01
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 2015-07
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
Ann. Oncol., 2013-12-01
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.
Nat Rev Clin Oncol, 2016-08-01
Biomarkers of residual disease after neoadjuvant therapy for breast cancer.
The Lancet. Oncology, 2018-02
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
N. Engl. J. Med.,
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Ann. Oncol.,
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
Clin. Cancer Res., 2018 Mar 26
ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors.
Science translational medicine, 2013-12-18
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-02
Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.
Ann. Oncol.,
Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG).
Int J Radiat Oncol Biol Phys, 2023 Mar 01
Alleviating morbidity from locally advanced breast cancer using a practical and short radiotherapy regime: Results of the HYPORT palliative studies.
Breast Cancer, 2012 Apr 25
Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.
Annals of surgical oncology, 2018-10
Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01.
Lancet Oncol., 2015 Sep 09
Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.
J Clin Oncol, 2022 Jan 07
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
JAMA oncology, 2019-06-01
Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial.
Lancet Oncol, 2021 Jun 11
Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial.
Cancer, 2004-10-15
Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment.
The New England journal of medicine, 2018-12-13
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Lancet Oncol., 2016 Jun 23
Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study.
BMJ, 2016 Sep 30
Revisiting the drug interaction between tamoxifen and SSRI antidepressants.
The New England journal of medicine, 2018-07-12
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Journal of the National Cancer Institute, 2017-02
Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial.
N Engl J Med, 2015 Jan 8
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Annals of internal medicine, 2018-01-16
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.
N Engl J Med, 2017 Nov 16
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-12-10
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.
The Lancet. Oncology, 2012-07
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.
Annu. Rev. Med., 2015 Aug 28
Adjuvant Bisphosphonates and Breast Cancer Survival.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-06-20
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
Lancet,
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
Lancet Oncol, 2019 Feb 19
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol, 2019 Dec 02
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
Lancet Oncol, 2017 Oct 13
Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.
JNCI Cancer Spectr, 2021 May 28
Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice.
Lancet (London, England), 2013-03-09
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
The New England journal of medicine, 2018-07-12
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Cancer, 2006-09-15
Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero.
Cancer Discov,
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Clin. Cancer Res.,
Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
N. Engl. J. Med.,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
J Clin Oncol, 2022 Apr 11
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
The New England journal of medicine, 2016-07-21
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
The Lancet. Oncology, 2019-01
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet. Oncology, 2017-12
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
J Thorac Oncol, 2016 Jul
Adjuvant Chemotherapy for T3 Non-Small Cell Lung Cancer with Additional Tumor Nodules in the Same Lobe.
Eur. J. Cancer, 2017 Aug 04
Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
J Thorac Oncol, 2018 Feb
Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy.
J. Clin. Oncol., 2018 Jun 15
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.
The Lancet. Oncology, 2015-02
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
J. Clin. Oncol., 2017 Dec 14
Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
NPJ breast cancer, 2017
CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data.
The New England journal of medicine, 2018-06-14
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
N Engl J Med, 2018 Oct 20
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
The Lancet. Respiratory medicine, 2017-11
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Ann. Thorac. Surg.,
Long-term survival after resection of primary adenoid cystic and squamous cell carcinoma of the trachea and carina.
Annals of surgical oncology, 2009-06
Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation.
Annals of surgical oncology, 2017-02
Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study.
Breast Cancer Res. Treat., 2017 Sep 15
Characteristics and prognosis of breast cancer after liver or kidney transplantation.
JAMA, 2011-11-02
Spectrum of cancer risk among US solid organ transplant recipients.
The New England journal of medicine, 2016-11-17
Palbociclib and Letrozole in Advanced Breast Cancer.
The Lancet. Oncology, 2016-04
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Breast cancer research : BCR, 2016-06-28
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
International journal of radiation oncology, biology, physics, 2009-01-01
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-12-10
Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer.
BMC Cancer, 2018 Jan 11
Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-07-01
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
Annals of surgical oncology, 2011-01
Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up.
J Clin Oncol, 2011 Jan 10
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-01
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-07-20
Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.
JAMA Oncol,
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
JAMA Oncol,
Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.
J. Clin. Oncol., 2020 Feb 20
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.
J Clin Oncol, 2019 Jun 02
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
The New England journal of medicine, 2016-11-10
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
The New England journal of medicine, 2018-05-31
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-03-01
Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
The Lancet. Oncology, 2013-10
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
Breast cancer research and treatment, 2017-06
Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-10
Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-04
What threshold for adjuvant therapy in older breast cancer patients?
The journals of gerontology. Series A, Biological sciences and medical sciences, 2001-03
Frailty in older adults: evidence for a phenotype.
Annals of oncology : official journal of the European Society for Medical Oncology, 2015-02
Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†.
Medicine (Baltimore),
The predictive accuracy of PREDICT: a personalized decision-making tool for Southeast Asian women with breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-01
Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Arch Surg,
Basic principles in surgical oncology.
Lancet, 1998 Jul 25
Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group.
Int. J. Radiat. Oncol. Biol. Phys., 2008-11-01
Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.
JAMA Oncol,
Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.
Lancet Oncol, 2021 Dec 15
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.
N Engl J Med, 2011 Oct 6
Adjuvant trastuzumab in HER2-positive breast cancer.
Lancet Oncol., 2012-01-01
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
JAMA oncology, 2017-05-01
Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2012-12-15
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.
JAMA oncology, 2017-07-01
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.
J. Clin. Oncol., 2017 Oct 02
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.
The New England journal of medicine, 2015-02-19
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Breast Cancer Res Treat, 2009 Jun
Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019-02
Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade.
JAMA, 2012 Jul 11
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Radiation oncology (London, England), 2011-09-28
Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
JAMA surgery, 2019-05-29
Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
J. Clin. Oncol., 2020 Feb 27
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Trials, 2013 Aug 19
WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial.
Ann. Oncol., 2012 Jun 06
Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.
Cancer,
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Annals of surgical oncology, 2014-10
Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
N. Engl. J. Med.,
Pembrolizumab for Early Triple-Negative Breast Cancer.
Ann Surg Oncol, 2022 Apr 04
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.
Clin Transl Oncol, 2018 Mar 28
Concurrent use of capecitabine with radiation therapy and survival in breast cancer (BC) after neoadjuvant chemotherapy.
Eur J Haematol, 2023 Mar 27
Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.
N. Engl. J. Med., 2017 Jun 04
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-04-15
Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer.
The New England journal of medicine, 2019-06-20
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
The New England journal of medicine, 2018-01-11
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
N. Engl. J. Med., 2019 May 31
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.
The New England journal of medicine, 2018-12-06
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
J Thorac Oncol, 2019 Jan 18
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.
The New England journal of medicine, 2019-02-14
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
N. Engl. J. Med.,
Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-01
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
The New England journal of medicine, 2012-02-09
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Cancer control : journal of the Moffitt Cancer Center, 2009-01
Endometrial cancer and Lynch syndrome: clinical and pathologic considerations.
JAMA, 2015-07-07
Female Hormonal Factors and the Risk of Endometrial Cancer in Lynch Syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2019-08-01
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.
Nat Commun, 2019 Mar 27
Diagnosis of fusion genes using targeted RNA sequencing.
Annals of surgery, 2019-04-05
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.
The Lancet. Oncology, 2010-01
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Breast Cancer Res. Treat.,
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-01
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-06-15
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
J. Natl. Cancer Inst.,
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
PLoS ONE, 2018 May 16
The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
International journal of radiation oncology, biology, physics, 2007-07-15
Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-12-01
Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
Lancet Oncol., 2015-03-01
Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.
Ann. Surg. Oncol., 2013 Nov 23
Breast-conserving surgery with or without radiotherapy in older breast patients with early stage breast cancer: a systematic review and meta-analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-01
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Lancet Oncol., 2014-06-01
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-02-01
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.
Breast, 2013 Dec 22
Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions.
Breast, 2015 Oct 09
Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab.
Cancer,
Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial.
J. Clin. Oncol., 2013 Aug 26
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Cancer, 2005-04-15
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.
Lung cancer (Amsterdam, Netherlands), 2015-12
HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.
Nature medicine, 2018-05
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Cancer, 2017-11-01
HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-08-20
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Lancet (London, England), 2019-05-04
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2015-07
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
European journal of cancer (Oxford, England : 1990), 2019-03
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
Lancet Oncol, 2019 May 20
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Lung Cancer, 2012 Feb 10
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
N. Engl. J. Med., 2019 Sep 28
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
JAMA, 2014-05-21
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Clin. Cancer Res., 2019 Aug 15
Crizotinib in -Deregulated or -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.
Ann. Oncol.,
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
Gastroenterology, 2018 May 17
Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
Clin. Gastroenterol. Hepatol., 2018 Nov 28
Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
Hepatology (Baltimore, Md.), 2019-10
Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
Cancer, 2011-11-01
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.
Case reports in oncology, 2017
Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura.
BMC Cancer, 2015 Oct 15
Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.
JAMA oncology, 2019-06-01
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
Int J Cancer, 2018 Apr 15
Biweekly cisplatin and gemcitabine in patients with advanced biliary tract cancer.
JAMA Oncol, 2019 Oct 31
Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Eur J Surg Oncol, 2014 Oct 07
Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis.
Breast cancer research and treatment, 2017-08
The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
Ann. Oncol.,
Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)
The Lancet. Oncology, 2018-01
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Annals of surgical oncology, 2018-08
Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.
Lancet Oncol., 2020 Feb 14
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.
The Lancet. Oncology, 2010-10
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
Breast Cancer Res. Treat.,
Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer.
Lancet, 2019 Oct 04
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
International journal of radiation oncology, biology, physics, 2005-07-15
Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-20
Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer.
Cancer discovery, 2015-08
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Annals of oncology : official journal of the European Society for Medical Oncology, 2018-10-01
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
Nature, 2014-07-31
Comprehensive molecular profiling of lung adenocarcinoma.
Cancer discovery, 2015-08
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
J Clin Oncol, 2020 May 10
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
J Thorac Oncol, 2021 Oct 12
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
J. Clin. Oncol., 2019 Oct 16
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
Proceedings of the National Academy of Sciences of the United States of America, 2015-11-03
Transcriptomic characterization of fibrolamellar hepatocellular carcinoma.
Oncologist, 2020 Mar 10
Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.
Semin Diagn Pathol, 2016 Dec 23
Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings.
Breast cancer research and treatment, 2014-11
Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research.
The Lancet. Oncology, 2016-03
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
British journal of cancer, 2005-03-14
Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study.
Case Rep Oncol, 2020 Jan 21
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-07-01
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
The New England journal of medicine, 2001-09-06
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-11-01
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
Lancet Oncol, 2020 Dec 07
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Ann Oncol,
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Lancet Oncol, 2021 Apr 13
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
J. Thorac. Cardiovasc. Surg.,
Prognostic factors and long-term results after thymoma resection: a series of 307 patients.
Cancer, 2015 Jan 06
Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: the Japanese Association for Research on the Thymus Database Study.
Eur J Cardiothorac Surg,
Report from the European Society of Thoracic Surgeons prospective thymic database 2017: a powerful resource for a collaborative global effort to manage thymic tumours.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-07-20
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-12-01
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
JAMA Oncol, 2020 Aug 13
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Journal of the National Cancer Institute, 2005-11-16
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10
Molecular Characterization and Mortality From Breast Cancer in Men.
N Engl J Med,
Micrometastases or isolated tumor cells and the outcome of breast cancer.
Lancet Oncol.,
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.
British journal of cancer, 2011-06-07
Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma.
N Engl J Med, 2021-04-01
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Cancer, 2020 Jun 10
Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-08-10
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Journal of the National Cancer Institute, 1997-11-19
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Journal of surgical oncology, 2017-06
Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 2000-08
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.
Lancet Oncol., 2018 Nov 06
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001-03-15
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis.
Clin Nutr, 2015 Aug 28
The association of substituting carbohydrates with total fat and different types of fatty acids with mortality and weight change among diabetes patients.
Obstet Gynecol,
Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study.
JAMA,
Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
Cancer Prev Res (Phila), 2019 Aug 16
Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Risk Biomarkers in High-Risk Women: A Pilot Study.
The New England journal of medicine, 2017-01-12
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Seminars in oncology, 2018-08
Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.
Endocrine-related cancer, 2016-09
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.
Pancreas, 2017-07
The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.
JAMA Oncol, 2020 Apr 16
Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.
Pancreas, 2020 Jan
The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.
Surg Oncol Clin N Am, 2020 Oct 20
Surgical Management of Neuroendocrine Tumor Liver Metastases.
Scand J Gastroenterol, 2019 Aug 01
Hepatic micrometastases outside macrometastases are present in all patients with ileal neuroendocrine primary tumour at the time of liver resection.
J Am Coll Surg, 2017 Jan 11
Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution.
J Clin Oncol, 2018 Jun 07
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Lu-Dotatate in the Phase III NETTER-1 Trial.
Lancet Oncol., 2014-11-01
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01
Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10
Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.
N. Engl. J. Med., 2017-07-27
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Ann. Oncol.,
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-02-01
Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
JAMA Oncol,
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.
Urology, 2001-08
Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer.
Br J Cancer,
Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.
The New England journal of medicine, 2016-03-03
Tumor Regression and Allograft Rejection after Administration of Anti-PD-1.
Cancer immunology, immunotherapy : CII, 2017-01
Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report.
Cancer, 2017-06-01
Immune checkpoint inhibitors in challenging populations.
Journal of the American Academy of Dermatology, 2019-07-11
Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review.
J Immunother,
Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma.
Oncologist, 2020 Feb 11
The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-09
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.
J Thorac Dis,
Lung neuroendocrine tumors: pathological characteristics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-03-10
Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
J Clin Oncol, 2019 Sep 18
Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline.
Gynecologic oncology, 2014-11
Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria.
Practical radiation oncology, 2019
Neoadjuvant Chemoradiation Therapy Followed by Extrafascial Hysterectomy in Locally Advanced Type II Endometrial Cancer Clinically Extending to Cervix.
Journal of clinical pharmacology, 2010-04
Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function.
BJU Int, 2011 Oct
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Anticancer Drugs,
Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults.
Cancer, 2010-11-15
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.
Ann Oncol, 2010 Feb 12
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
N Engl J Med, 2021 Mar 4
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Cancer, 2000-03-15
Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience.
Front Oncol, 2020 Dec 03
Multiple Microinvasion Foci in Ductal Carcinoma Is Associated With an Increased Risk of Recurrence and Worse Survival Outcome.
Annals of surgical oncology, 2018-07
Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer.
Clinical genitourinary cancer, 2018-12
Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery.
J Urol, 2020 Apr
Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma.
Lancet, 2020 Mar 05
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
The New England journal of medicine, 2018-07-05
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Lancet (London, England), 2018-03-24
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
J Gastroenterol, 2019 Nov 12
REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
Am Heart J, 2010 Sep 18
Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
N Engl J Med,
Sorafenib in advanced hepatocellular carcinoma.
Lancet (London, England), 2017-01-07
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet. Oncology, 2019-02
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
JAMA Oncol, 2020 Dec 10
Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
Hepatology, 2019 Oct 14
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
Clin Imaging, 2021 Feb 10
Adenomyoepithelioma of the breast: Case series and literature review.
N Engl J Med, 2020 May 14
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.
The New England journal of medicine, 2017-07-27
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
JAMA Oncol, 2021 Feb 18
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Clinical breast cancer, 2008-06
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Clinical genitourinary cancer, 2017-06
Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review.
The Journal of urology, 2014-02
Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns.
Journal of the National Comprehensive Cancer Network : JNCCN, 2018-01
Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Cancer medicine, 2019-01
Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults.
Journal of the National Cancer Institute, 1988-07-06
The role of methotrexate in osteosarcoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 2015-02
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Anticancer Drugs,
Perioperative chemotherapy with and without high-dose methotrexate in adult osteosarcoma.
J Adolesc Young Adult Oncol, 2019 Nov 08
Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years.
N. Engl. J. Med., 2018-01-25
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
N. Engl. J. Med., 2019 Jun 02
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N. Engl. J. Med., 2019 May 31
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-02-01
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
J. Clin. Oncol., 2019 Jul 22
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
Breast Cancer Res, 2020 Nov 04
A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations.
Breast Cancer Res Treat, 2011 Jul 27
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era.
Clin Breast Cancer, 2019 May 24
Adjuvant Treatment of Triple-Negative Metaplastic Breast Cancer With Weekly Paclitaxel and Platinum Chemotherapy: Retrospective Case Review From a Single Institution.
J Clin Oncol, 2020 Sep 16
Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-12-01
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-07-10
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-07-10
Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
Oncologist, 2020 Dec 03
Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
International journal of radiation oncology, biology, physics, 2018-10-01
Optimizing the Role of Surgery and Radiation Therapy in Urethral Cancer Based on Histology and Disease Extent.
Urology, 2000-11-01
Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies.
Abdom Radiol (NY), 2019 Aug 29
Apical periurethral transition zone lesions: MRI and histology findings.
Ann Oncol, 2007 Nov 15
Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
Cancer Manag Res, 2012 Jun 13
Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution.
Ann Oncol, 2007 Feb 13
Pattern and prognostic factors in patients with malignant ascites: a retrospective study.
J Clin Oncol, 2021 Feb 04
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
Biol Blood Marrow Transplant, 2019 Jul 01
Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party.
Ann Hematol, 2015 Mar 27
Management of chronic myeloid leukemia in blast crisis.
Leukemia, 2008-12
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Leuk Lymphoma, 2019 Nov 04
Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Ann Oncol, 2019 Oct 1
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Int J Cancer, 2020 Dec 21
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.
Adv Ther, 2020 Oct 29
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Lancet, 2021 May 07
F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
N. Engl. J. Med., 2016-10-13
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
Lancet, 2020 Sep 28
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
Lancet Oncol,
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
Lancet Oncol,
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
J Urol, 2020 Apr 13
Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Reply.
Eur J Nucl Med Mol Imaging, 2020 Aug 12
Pelvic lymph-node staging with F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.
J Urol,
Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology.
Gynecologic oncology, 2019-06
Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells.
Gynecol Oncol, 2021 Mar 05
Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
Zhonghua Bing Li Xue Za Zhi,
[Clinicopathological characteristics of pediatric-type follicular lymphomas: an analysis of 37 cases].
Am J Transplant, 2016 Jun 09
The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors.
Transplantation, 2021 Apr 27
Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors.
Surgery, 2017 Jun 16
Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review.
JAMA, 2011-02-09
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
Clinical genitourinary cancer, 2018-06
Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy.
Cancer treatment and research communications, 2019
Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.
Urology, 2013-06
Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.
Prostate Cancer Prostatic Dis, 2020 Feb 28
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.
Cancer, 2019 Dec 1
Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.
J Clin Oncol, 2021 Feb 02
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-01
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options--An Analysis From the Global Germ Cell Cancer Group.
Cancer, 2020 Mar 15
High-dose chemotherapy plus peripheral blood stem cell transplantation for patients with relapsed germ cell tumors and active brain metastases.
J Clin Oncol, 2021 Apr 06
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
Eur J Nucl Med Mol Imaging, 2018 Sep 28
Salvage peptide receptor radionuclide therapy with [Lu-DOTA,Tyr]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.
Br J Radiol, 2018 Mar 20
Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response.
Eur J Nucl Med Mol Imaging, 2013 Sep 13
Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours.
BMC Cancer, 2019 Aug 08
Salvage PRRT with Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival.
Scand J Gastroenterol, 2021 Jan 20
Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study.
Int J Endocrinol, 2021 Jan 23
The Safety and Efficacy of the Repeated PRRT with [Y]Y/[Lu]Lu-DOTATATE in Patients with NET.
Cancer Treat Rev, 2020 Dec 22
Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis.
Clin Cancer Res,
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.
The New England journal of medicine, 2012-05-10
Lenalidomide after stem-cell transplantation for multiple myeloma.
Nature communications, 2019-04-23
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Blood, 2012 Aug 13
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
J Clin Oncol, 2020 Apr 16
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
Blood,
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-10-10
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
The New England journal of medicine, 2017-04-06
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
The Lancet. Oncology, 2019-01
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Blood,
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Lancet Oncol, 2020 Jan
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Eur J Cancer, 2020 Jun 27
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
European urology focus, 2018-12
Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder.
Int J Radiat Oncol Biol Phys, 2015 Jul 15
Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients.
Clin Genitourin Cancer, 2019 Mar 28
Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study.
Int J Radiat Oncol Biol Phys, 2021 Feb 06
Treatment Outcomes for Small Cell Carcinoma of the Bladder: Results From a UK Patient Retrospective Cohort Study.
Circulation, 1995-08-15
Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-01
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
Endocrine-related cancer, 2018-03
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
Lancet, 2021 Jan 21
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Ann Oncol,
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
The New England journal of medicine, 2018-11-08
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Eur J Haematol, 2021 Aug 11
Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM).
Lancet Oncol, 2020 Oct 29
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
Blood Adv, 2021 Sep 01
Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Cell,
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.
Am J Hematol, 2021 Jul 05
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials.
The Lancet. Oncology, 2018-07
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Blood Cancer J, 2020 Mar 09
Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis.
JAMA Oncol,
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
JAMA, 2016-11-15
Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage.
N Engl J Med,
A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.
J Clin Oncol, 2019 Apr 10
Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.
J Clin Oncol, 2020 Feb 21
Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial.
J Clin Oncol, 2020 Oct 06
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.
Mol Cell Endocrinol, 2021 Jan 26
Hormone replacement therapy after breast cancer: Yes, No or maybe?
Journal of clinical pathology, 2017-09
Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma.
Leukemia, 2018-06
Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset.
Int J Cancer, 2018 May 10
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.
J. Clin. Oncol., 2020 Sep 20
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Haematologica, 2021 Jun 01
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
J Urol, 2021 Feb 26
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with F-DCFPyL in Prostate Cancer Patients (OSPREY).
European urology, 2019-06
The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.
N Engl J Med, 2020 Sep 18
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
Cancer, 2020 Nov 20
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.
Ann. Surg., 2019 Aug 30
Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas.
Annals of surgical oncology, 2019-04
Survival in Patients with High-Grade Colorectal Neuroendocrine Carcinomas: The Role of Surgery and Chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10
Outcome of deferred initial therapy in mantle-cell lymphoma.
The New England journal of medicine, 2015-11-05
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
Haematologica, 2018 May 24
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of mutations in mantle cell lymphoma.
Blood,
p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis.
Leukemia, 2011 Jul 01
Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.
Haematologica, 2019 Sep 19
mutations and disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
Blood, 2017 Aug 17
mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
Blood, 2015 May 28
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
BJU international, 2011-09
Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710).
Cancer, 2009-09-15
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-04-01
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
Clinical genitourinary cancer, 2016-02
Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation.
Cancer, 2019-05-01
Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
European urology, 2017-07
Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.
Int Urol Nephrol, 2007 Mar 02
The effect of squamous and/or glandular differentiation on recurrence, progression and survival in urothelial carcinoma of bladder.
Clin Genitourin Cancer, 2017 Jul 22
Squamous Differentiation Predicts Poor Response to Cisplatin-Based Chemotherapy and Unfavorable Prognosis in Urothelial Carcinoma of the Urinary Bladder.
Clin Genitourin Cancer, 2020 Feb 08
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study.
Eur Urol, 2019 Nov 08
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
J Clin Oncol,
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.
Clin Lymphoma Myeloma Leuk, 2020 Mar 07
Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.
Clin Lymphoma Myeloma Leuk, 2021 Jul 18
Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma.
Blood Cancer J, 2021 Jan 11
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.
N Engl J Med,
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Blood cancer journal, 2018-06-12
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.
J. Clin. Oncol., 2019 Oct 25
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
JAMA Oncol,
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.
J Urol, 2020 Jul
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.
Clin Cancer Res, 2020 Jan 22
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.
Cancer, 2021 Apr 21
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort.
British journal of haematology, 2014-06
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
International journal of radiation oncology, biology, physics, 2019-06-01
Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04
Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Blood, 2018-07-05
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
Blood,
Getting to transplant in Hodgkin lymphoma: BVB.
Blood,
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
J Clin Oncol, 2021 Jun 25
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Eur Urol Oncol, 2019 Sep 19
Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study.
N Engl J Med,
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Invest New Drugs, 2017 Oct 25
Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature.
Lancet Oncol, 2019 Oct 23
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.
Blood, 2011-09-15
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Haematologica, 2011 Dec 01
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.
Cancer Chemother Pharmacol, 2016 Jun 10
Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
Clin Cancer Res, 2020 Aug 17
Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation.
N. Engl. J. Med., 2012-04-19
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.
British journal of haematology, 2017-11
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
J Clin Oncol, 2016 Feb 29
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
Lancet Haematol, 2016 Dec 05
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
Lancet Oncol, 2022 Jan 21
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
N Engl J Med,
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Annals of Oncology, 2021 Sep 29
Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study.
Prostate cancer and prostatic diseases, 2018-04
Platinum sensitivity in metastatic prostate cancer: does histology matter?
JCO Precis Oncol, 2020
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations.
Lancet Oncol, 2019 Sep 09
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Cancer, 2019 Jul 18
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
J Clin Oncol, 2021 Dec 10
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
The Lancet. Oncology, 2014-02
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.
Front Oncol, 2018 Apr 17
Local and Regional Breast Cancer Recurrences: Salvage Therapy Options in the New Era of Molecular Subtypes.
Br J Cancer, 2021 Feb 03
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.
Hepatogastroenterology, 2013 Jan 16
Alpha-fetoprotein: the predictor of microvascular invasion in solitary small hepatocellular carcinoma and criterion for anatomic or non-anatomic hepatic resection.
Medicine (Baltimore),
Post-treatment alpha-fetoprotein response predicts prognosis of patients with hepatocellular carcinoma: A meta-analysis.
J Clin Oncol, 2022 Jan 18
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
J Clin Oncol, 2021 Aug 13
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
Lancet, 2016 Mar 19
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
N Engl J Med, 2022 Feb 17
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-20
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-05-10
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.
Lancet, 2019 Dec 12
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Lancet (London, England), 2016-02-27
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Blood, 2015-03-26
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
Clin Lymphoma Myeloma Leuk, 2019 Oct 09
Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.
JCO Oncol Pract, 2019 Nov 25
Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions.
Lancet Haematol,
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Leukemia, 2020 Jul 21
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.
Am Soc Clin Oncol Educ Book,
Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.
World J Gastroenterol,
Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis.
Prostate, 2022 Jun 08
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Lancet (London, England), 2019-01-19
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Lancet Oncol, 2014 Oct 26
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Blood cancer journal, 2016-07-29
Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.
Leukemia, 2022 Apr 11
Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.
The New England journal of medicine, 2018-08-23
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Breast Cancer Res Treat, 2016 Feb 18
Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.
Mol Cancer Ther, 2018 Mar 28
Trastuzumab-Resistant HER2 Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition.
Eur J Cancer, 2014 Aug 12
Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
N Engl J Med, 2021 Jun 03
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
N Engl J Med, 2022 Jun 05
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Ann Oncol, 2013 Mar 01
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).
N Engl J Med, 2020 Sep 19
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.
Lancet, 2021 Sep 20
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
N Engl J Med, 2022 Apr 11
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Lancet (London, England), 2014-07-12
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-05-20
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
N Engl J Med, 2022 Dec 11
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
J Clin Oncol, 2022 Dec 22
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Blood Adv, 2022 May 10
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.
Blood, 2022 Dec 15
Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis.
Oncotarget,
Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-06-10
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.
Clinical genitourinary cancer, 2018-08
Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function.
Pediatr Blood Cancer, 2022 Oct 02
Irinotecan dose schedule for the treatment of Ewing sarcoma.
Clin Cancer Res, 2023 Jan 09
Longer versus shorter schedules of vincristine, irinotecan and temozolomide (VIT) for relapsed or refractory Ewing sarcoma: a randomized controlled phase 2 trial.
Journal of the National Comprehensive Cancer Network : JNCCN, 2012-05
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-09-15
Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy.
Cancer, 2010-09-15
Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients.
Pediatric blood & cancer, 2006-03
APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial.
Pediatric blood & cancer, 2014-04
Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-20
Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001-05-01
Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912.
Annals of oncology : official journal of the European Society for Medical Oncology, 2011-02
Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma.
Pediatric blood & cancer, 2015-01
Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.
The Lancet. Oncology, 2018-09
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
N Engl J Med, 2022 Nov 03
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.
Lancet, 1993 Apr 24
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.
Lancet, 2002 Jun 15
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Crit Rev Oncol Hematol, 2014 May 02
High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis.
Br J Haematol, 2014 Feb 07
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Blood, 2023 Apr 27
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.
J Clin Oncol, 2005 Sep 01
Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group.
J Pediatr Hematol Oncol, 2004 Nov
Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease.
Hemasphere, 2020 Jan 10
Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group.
J Pediatr Hematol Oncol, 2001 Jan
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Br J Cancer, 1992 Dec
Outcome of children with resistant and relapsed Hodgkin's disease.
Int J Radiat Oncol Biol Phys, 2001 Dec 01
Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial.
J Clin Oncol, 2007 Apr 09
Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-01-15
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
N Engl J Med, 2022 Jun 03
Adagrasib in Non-Small-Cell Lung Cancer Harboring a Mutation.
Oncology, 2020 May 28
The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel.
Ann Surg,
Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.
Blood, 2016 Mar 21
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Amyloid, 2017 Apr 23
Amyloid in bone marrow smears in systemic light-chain amyloidosis.
Leukemia, 2015 Oct 07
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.
British journal of haematology, 2017-10
Natural history of amyloidosis isolated to fat and bone marrow aspirate.
Blood Adv,
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.
Blood Cancer J, 2018 May 24
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.
Amyloid, 2019 Jan 20
Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.
Front Oncol, 2021 Apr 29
Clinical Relevance of Tubular Breast Carcinoma: Large Retrospective Study and Meta-Analysis.
The New England journal of medicine, 2015-08-13
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
J Clin Oncol, 2022 Aug 12
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.
Annals of oncology : official journal of the European Society for Medical Oncology, 1993-11
High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients.
Proc Natl Acad Sci U S A, 2019 Apr 15
Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
N Engl J Med,
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Ann Oncol, 2022 Feb 14
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.
N Engl J Med,
GPRC5D-Targeted CAR T Cells for Myeloma.
Ann Oncol, 2009 Jul 01
High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
Blood, 2010 Jul 21
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Lancet (London, England), 2019-06-15
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
Clin Lymphoma Myeloma Leuk, 2020 Jul 29
Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis.
Br J Haematol, 2021 Aug 15
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Blood, 2022 Dec 08
Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score.
Chest, 2020 Aug 14
Clinical Characteristics of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: A Retrospective Analysis.
Chest, 2020 Jul
Somatostatin Analogs Improve Respiratory Symptoms in Patients With Diffuse Idiopathic Neuroendocrine Cell Hyperplasia.
ERJ Open Res, 2020 Oct
Constrictive bronchiolitis in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia.
N Engl J Med, 2022 Jun 05
Teclistamab in Relapsed or Refractory Multiple Myeloma.
J Clin Oncol, 2022 Jun 04
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
J Clin Oncol, 2022 Oct 21
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2007-11
Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer.
Annals of surgery, 2010-03
Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas.
Cancer, 2016-02-15
The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
Cancer, 2019-01-01
Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer.
HPB : the official journal of the International Hepato Pancreato Biliary Association, 2017-07
Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
N. Engl. J. Med.,
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Leukemia, 2019-03
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.
Journal of the American Society of Nephrology : JASN, 2007-03
Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.
Lancet Haematol, 2019 Mar 11
High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.
Blood Cancer J, 2022 Sep 02
Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma.
N Engl J Med, 2022 Jun 03
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
J Hematol Oncol, 2021 Oct 30
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Blood, 2022 Mar 03
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Lancet,
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
N Engl J Med, 2021 Dec 11
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
Cancer, 2021 Jun 28
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.
Nature reviews. Urology, 2018-04
Clinical implications of PTEN loss in prostate cancer.
JAMA Oncol,
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
Clin Cancer Res, 2019 Sep 11
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-20
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.
BMC Cancer, 2019 Aug 19
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Leukemia, 2022 Feb 21
Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.
J. Clin. Oncol., 2018-07-01
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
The New England journal of medicine, 2023 Jun 04
Overall Survival with Osimertinib in Resected -Mutated NSCLC.
Nat Rev Urol, 2021 Jan 11
Defining cisplatin eligibility in patients with muscle-invasive bladder cancer.
J Clin Oncol, 2022 Aug 30
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
Lancet Oncol., 2019 Mar 25
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
Cancer cell, 2017-06-12
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
J Neurooncol, 2022 Jun 20
Chemotherapy is an efficient treatment in primary CNS MALT lymphoma.
N Engl J Med,
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
J Clin Oncol, 2020 Dec 23
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Nat Med, 2020 Apr 06
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
J Clin Oncol, 2021 Oct 12
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
Nat Cancer, 2020 Aug 03
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
Eur Urol Oncol, 2022 May 20
Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.
J Clin Oncol, 2021 Dec 20
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
Lancet Oncol, 2020 Jun 05
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Lancet Oncol, 2022 Jul 12
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Lancet, 2021 Jun 24
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
N Engl J Med, 2023 Jun 05
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
N Engl J Med, 2023 Feb 10
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Lancet Oncol, 2021 Dec 03
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Lancet, 2021 Jun 04
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Blood, 2022 Oct 20
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
J Clin Oncol, 2017 Jan 17
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Br J Haematol, 2023 Jun 07
Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
Experimental hematology & oncology, 2022 Feb 28
Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis.
JACC CardioOncol, 2021 Mar 16
The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil-Associated Coronary Vasospasm.
JACC. CardioOncology, 2020 Nov 17
How to Diagnose and Manage Patients With Fluoropyrimidine-Induced Chest Pain: A Single Center Approach.
Annals of surgery, 2010-09
Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.
Journal of reconstructive microsurgery, 2022 Feb 14
National Outcomes of Prophylactic Lymphovenous Bypass during Axillary Lymph Node Dissection.
Annals of surgery open : perspectives of surgical history, education, and clinical approaches, 2023 May 02
Prophylactic Lymphovenous Bypass at the Time of Axillary Lymph Node Dissection Decreases Rates of Lymphedema.
The Lancet. Oncology, 2011 Dec 13
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
American journal of hematology, 2022 Jul 05
Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study.
Blood advances, 2023 Oct 24
Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.
Blood, 2018 Aug 14
Treatment of AL amyloidosis with bendamustine: a study of 122 patients.
Leukemia, 2024 Apr 09
Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures.
American journal of hematology, 2016-09
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.
Blood, 2017 Jun 13
How I treat patients with aggressive lymphoma at high risk of CNS relapse.
Haematologica, 2013-01
Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience.
The Lancet. Haematology, 2015 May 06
Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study.
European respiratory review : an official journal of the European Respiratory Society, 2017 Sep 06
The lung in amyloidosis.
Mayo Clinic proceedings, 2017-06
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience.
Blood Cancer J, 2022 Sep 14
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study.
The Journal of community and supportive oncology, 2014-10
Informational needs and the quality of life of patients in their first year after metastatic breast cancer diagnosis.
Journal of the National Cancer Institute, 1996-10-16
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
The oncologist, 2019-03
Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Breast cancer research and treatment, 2019-04
Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2020 Apr 22
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.
Annals of oncology : official journal of the European Society for Medical Oncology, 2020 Sep 23
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
Annals of surgical oncology, 2020 Oct 30
Benefits of Surgical Treatment of Stage IV Breast Cancer for Patients With Known Hormone Receptor and HER2 Status.
JAMA oncology, 2021 Jan 01
Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis.
Annals of oncology : official journal of the European Society for Medical Oncology, 2021 Oct 19
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 May 26
Impact of F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer.
Journal of the National Comprehensive Cancer Network : JNCCN, 2020 Sep
Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy.
Radiology, 2012 Dec 06
Performance of FDG PET/CT in the clinical management of breast cancer.
J Thorac Oncol, 2023 Feb 23
Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC: A Post-Hoc Subgroup Analysis from PACIFIC.
J Clin Oncol, 2023 Jan 31
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
Cancer journal (Sudbury, Mass.), 2020 Nov/Dec
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer: Implications for Oncogene-Driven Lung Cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021 Feb 12
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
Journal for immunotherapy of cancer, 2021 Aug
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
International journal of cancer, 2019 Feb 19
EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies.
The Lancet. Respiratory medicine, 2023 May 05
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Annals of surgical oncology, 2019 Jun 21
Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer.
Lancet Oncol, 2020 Apr 27
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
JAMA, 2023 Aug 8
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Blood, 2017 Jan 31
Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.
JAMA oncology, 2024 Jan 01
Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer.
Clinical breast cancer, 2018 Apr 18
Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: A Retrospective Review.
Breast cancer research and treatment, 2011 Jan 08
Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer.
Blood, 2023 Nov 30
Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas.
Cancer, 2011-10-01
Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy.
BMC Cancer, 2006 May 05
Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study.
International journal of radiation oncology, biology, physics, 1998-07-15
Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy.
International journal of radiation oncology, biology, physics, 2006-01-01
Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients.
Blood, 2014 May 29
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma.
Blood, 2014 Jun 17
Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis.
International journal of radiation oncology, biology, physics, 2011 Jan 27
Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy.
Leukemia & lymphoma, 2021 Feb 03
Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses.
Dominion law reports, 1990 Mar 30
Malette v. Shulman.
Blood, 2020 Apr 09
Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study.
American journal of hematology, 2019-04
Progression with clinical features is associated with worse subsequent survival in multiple myeloma.
Blood advances, 2023 Mar 28
Outcomes after biochemical or clinical progression in patients with multiple myeloma.
American journal of hematology, 2023 Jul 08
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021 Dec 13
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Blood, 2013-10-24
The impact of response on bone-directed therapy in patients with multiple myeloma.
The Lancet. Oncology, 2018-03
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Blood cancer journal, 2024 Apr 15
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.
Blood cancer journal, 2019 Nov 25
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
British journal of haematology, 2019 Dec 09
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.
The New England journal of medicine, 2023 Dec 12
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Blood cancer journal, 2024 Apr 22
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Blood advances, 2023 Sep 26
Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study.
Lancet (London, England), 2019 Dec 10
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
The New England journal of medicine, 2024 Jun 03
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Nature medicine, 2024 Jun 03
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
Blood, 2023 Jan 19
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
The New England journal of medicine, 2024 Jun 01
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
The New England journal of medicine, 2024 Jun 02
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
Clinical pharmacokinetics, 2017 Feb
Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.
Cancer chemotherapy and pharmacology, 2016 Dec 30
Population pharmacokinetics of lenalidomide in multiple myeloma patients.
Blood cancer journal, 2018-11-19
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Jun 06
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Oct 31
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Jun 06
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.
Transplant Cell Ther, 2023 Mar 17
Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Oct 24
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
Blood advances, 2023 Aug 22
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.
Kidney international, 2018-07
Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft.
BMC nephrology, 2019-02-14
Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.
Leukemia & lymphoma, 2024 Apr 16
Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL).
International journal of radiation oncology, biology, physics, 2024 Oct 27
Irradiated Bone Marrow Volume is Associated with Hematologic Toxicity in Patients with Multiple Myeloma.
Scientific reports, 2022 Nov 29
High-dose extended-field radiotherapy plus chemotherapy improved survival in extranodal NK/T-cell lymphoma in a real-life setting: results from the multicenter T-Cell Brazil Project.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-12-10
Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
Blood, 2015 Jun 24
Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009 Oct 05
Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-03-20
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001-05-01
Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access.
Chinese clinical oncology, 2019 Oct
The state of hepatic artery infusion chemotherapy in the management of metastatic colorectal cancer to the liver.
JAMA Oncol, 2019 Oct 31
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Blood, 2024 Aug 08
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Nature medicine, 2023 Aug 15
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
The New England journal of medicine, 2024 Dec 09
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Blood cancer journal, 2020 Oct 16
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
Blood advances, 2023 Nov 14
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.

Related Topics

Copyright © 2024 theMednet
All Rights Reserved.